

Regulation of replicative histone RNA metabolism by the histone chaperone ASF1

Shweta Mendiratta, Dominique Ray-Gallet, Sébastien Lemaire, Alberto

Gatto, Audrey Forest, Maciej Kerlin, Geneviève Almouzni

▶ To cite this version:

Shweta Mendiratta, Dominique Ray-Gallet, Sébastien Lemaire, Alberto Gatto, Audrey Forest, et al.. Regulation of replicative histone RNA metabolism by the histone chaperone ASF1. Molecular Cell, 2024, 84 (4), pp.791-801.e6. 10.1016/j.molcel.2023.12.038 . hal-04543988

HAL Id: hal-04543988 https://hal.science/hal-04543988

Submitted on 16 Apr 2024 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Regulation of replicative histone RNA metabolism by the histone chaperone ASF1

Shweta Mendiratta^{1,4*}, Dominique Ray-Gallet^{1*}, Sébastien Lemaire^{1**}, Alberto Gatto^{1,5**}, Audrey Forest¹, Maciej A. Kerlin^{2,3,6} and Geneviève Almouzni^{1,7***}

¹Institut Curie, PSL Research University, Sorbonne Université, CNRS UMR3664, Laboratoire Dynamique du Noyau, Equipe Labellisée Ligue contre le Cancer, 75005 Paris, France

²Institut Curie, PSL Research University, Sorbonne Université, CNRS UMR3664, Laboratoire Dynamique du Noyau, 75005 Paris, France.

³Institut Curie, PSL Research University, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, 75005 Paris, France

⁴Present address: Department of Biochemistry and Molecular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA

⁵Present address: Roche Diagnostics, 2881 Scott Blvd, Santa Clara, CA 95050, USA

⁶Present address: Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland

⁷Lead Contact

*These authors contributed equally

**These authors contributed equally

***Corresponding author: genevieve.almouzni@curie.fr

SUMMARY

In S phase, duplicating and assembling the whole genome into chromatin requires upregulation of replicative histone gene expression. Here, we explored how histone chaperones control histone production in human cells to ensure a proper link with chromatin assembly. Depletion of the ASF1 chaperone specifically decreases the pool of replicative histones both at the protein and RNA levels. The decrease in their overall expression, revealed by total RNA-seq, contrasted with the increase in nascent/newly synthesized RNAs observed by 4sU-labeled RNA-seq. Further inspection of replicative histone RNAs showed a 3'-end processing defect with an increase of pre-mRNAs/unprocessed transcripts likely targeted to degradation. Collectively these data argue for a production defect of replicative histone RNAs in ASF1-depleted cells. We discuss how this regulation of replicative histone RNA metabolism by ASF1 as a "chaperone checkpoint" fine-tunes the histone dosage to avoid unbalanced situations deleterious for cell survival.

KEYWORDS: replicative histone, histone chaperone, Anti-Silencing Function 1 (ASF1), Chromatin Assembly Factor-1 (CAF-1), RNA metabolism, 3'-end processing.

INTRODUCTION

Histones are the protein components of the basic unit of chromatin, the core particle of the nucleosome, which consists of a (H3-H4)₂ tetramer flanked by two H2A-H2B dimers around which 147 bp of DNA wraps.^{1,2} They play a central role in defining chromatin states associated with distinct cell fates. They are classified into replicative and non-replicative/replacement histone variants. While the latter do not exhibit S phase regulation in their expression, the replicative histone variants show a major peak in expression in early S phase to support chromatin assembly during genome replication.³⁻⁵ Beside distinct regulation in expression timing, replicative and non-replicative histone genes also differ in their genomic organization and RNA structure. In most metazoans, the replicative histone genes organized in clusters lack introns 4-6 and are expressed in specialized nuclear bodies known as histone locus bodies (HLBs).^{7,8} Their mRNAs do not contain a polyA tail but present a 3'conserved stem loop (SL) structure bound by Stem-Loop Binding Protein (SLBP), a key factor in replicative histone RNA metabolism. ^{4,6} These distinct features enable to provide the increase for histone supply ensuring nucleosome assembly during genome duplication in S phase. During the G1/S phase transition, a ~40-fold increment in histone mRNA levels involves the upregulation of both transcription and 3'-end processing.⁹ This cell-cycle regulation also implicates Nuclear protein ataxiatelangectasia (NPAT) and Flice-associated huge protein (FLASH), the core components of the HLB. 4-6

From their synthesis in the cytoplasm to their delivery to the chromatin or after eviction, histones are always escorted by histone chaperones.^{10,11} This prevents free positively charged histones to engage into promiscuous interactions with acidic partners, notably with DNA, that

could form aberrant aggregates in the cell. During replication in human cells, two main chaperones ensure the deposition of H3-H4 onto DNA: Chromatin assembly factor 1 (CAF-1) comprising three subunits (p150/CHAF1A, p60/CHAF1B and p48)^{12,13} and Anti-silencing factor 1 (ASF1), with two paralogs in mammals ASF1a and ASF1b¹⁴ and originally identified in veast.¹⁵ Interestingly, on the one hand, ASF1 binds the newly synthesized replicative histones H3.1/H3.2-H4 to transfer them to CAF-1, for deposition in a DNA synthesis-coupled (DSC) manner.^{16,17,18} On the other hand, ASF1 binds newly synthesized non-replicative histone H3.3 to transfer them to the Histone regulator A (HIRA) complex for deposition in a DNA synthesisindependent (DSI) manner. ^{16,19,20} In addition, ASF1 also promote histone recycling during replication and transcription.²¹⁻²³ Finally, in human cells, ASF1 but not CAF-1, also provides a buffering system for histone excess generated in response to stalled replication.²⁴ However, how these chaperones may impact histone RNA metabolism in mammals and other metazoans had remained unexplored. This is particularly interesting given that in budding yeast, where there are no distinct replicative and non-replicative H3 variants, the single ASF1 ortholog participates in activating histone gene transcription in S phase and transcriptional repression outside S phase in combination with Hir1, the budding yeast counterpart of HIRA.²⁵

Here, by exploring in human cells the effect of depleting either ASF1 or CAF-1 on the protein and RNA levels of replicative histones, we find that ASF1 impacts the regulation of replicative histone RNA metabolism.

RESULTS

ASF1 depletion, in contrast to CAF-1 depletion, reduces replicative histones at the levels of both soluble protein and total RNA

We considered how, in mammals, particular features control replicative histone synthesis and usage from gene to chromatin (Figure 1A, scheme) and focused on ASF1 and CAF-1. We analyzed the effect of their respective depletion on replicative histories both at protein and RNA levels. For comparison, we also used conditions known to affect either the synthesis of replicative histones by depleting FLASH^{26,27} or DNA replication by treating the cells with hydroxyurea (HU).²⁸ We transfected HeLa cells with siRNAs targeting ASF1a and ASF1b together (siASF1), the p60 subunit of CAF-1 (sip60), FLASH (siFLASH) or control (siCtrl). We depleted both ASF1a and ASF1b paralogs, since they most often compensate the depletion of the other.^{14,29} We then performed a pulse of EdU, 48 hrs post-transfection with siRNA, or 24 hrs post-treatment with HU (0.1 mM) and harvested cells to analyze their cell cycle by FACS and their DNA replication by EdU labeling. We prepared proteins in either whole, cytosolic, nuclear and chromatin fractions, and in parallel total RNAs (experimental scheme Figure 1B). Whole cell extracts served to verify depletion efficiencies for ASF1 and CAF-1 p60 (Figure S1A). For FLASH, since the commercial antibodies we tested did not function in Western blot, we controlled the depletion efficiency by immunofluorescence. The presence of FLASH at HLBs ³⁰, observed as foci in control cells, disappeared after siFLASH treatment (Figure S1A). FACS analysis showed an accumulation of cells in S phase in all conditions as compared to control cells (siCtrl and -HU), somewhat less pronounced for CAF-1 p60 depletion (Figure 1C). The defect in

S phase progression in all conditions correlated with the decrease of EdU labeling intensity as compared to controls, indicating replication alteration (Figures S1B and S1C).

We then estimated the amounts of the replicative histone H3.1 and H3.2 (recognized simultaneously by the same antibody) and of the non-replicative histone H3.3 in chromatin fraction and soluble cytosolic extract by Western blot. In chromatin fraction, all depletions reduced H3.1/H3.2, with ASF1 depletion giving the most extreme reduction (Figure 1D, left). Strikingly, in soluble cytosolic extract only ASF1 and FLASH depletions led to a strong decrease of H3.1/H3.2 (Figure 1D, right) without major changes for H3.3, except for FLASH depletion where H3.3 increased to possibly compensate the decrease of H3.1/H3.2 (Figure 1D). Thus, ASF1 depletion impacts replicative H3.1/H3.2 differently from HU-defect and from CAF-1 depletion. After HU treatment where DNA replication is altered, only a weak decrease of H3.1/H3.2 occurred in cytosolic extract while for CAF-1 p60 depletion, we rather saw an increase (Figure 1D, right). Indeed, under CAF-1 limitation, soluble H3.1/H3.2 likely accumulate due to defect in deposition. The decrease of cytosolic H3.1/H3.2, for FLASH and ASF1 depletions, prompted us to examine a role of ASF1 in replicative histone synthesis. We confirmed our findings by using different siRNAs targeting ASF1a and b (Figure S1D) and in soluble nuclear extracts (Figure S1E). Furthermore, given that cytosolic replicative histone H2B and H4 also decreased in ASF1-depleted cells (Figure S1F), ASF1 depletion may affect broadly most replicative histones in a coordinated fashion.

To examine effects at an RNA level, we performed RT-qPCR using total RNA to evaluate changes in the amount of replicative histone transcripts after ASF1, p60 and FLASH depletions or HU treatment. Total RNA corresponding to the replicative histone genes H2AC20, H1-4, H4C12 and H3C14 (encoding H2A, H1, H4 and H3, respectively) all decreased most

significantly in ASF1-depleted cells and in HU-treated cells (with the strongest decrease for siASF1) (Figure 1E). In contrast, total RNA did not decrease for the non-replicative histone genes H3-3A and H3-3B (both encoding H3.3) (Figure 1E). Moreover, we rescued the defect in replicative histones by expressing Strep-tagged ASF1a and b in siASF1-depleted HeLa cells (Figure S2A). Depleting SLBP, also involved in regulating replicative histone synthesis ^{31,32}, compared to FLASH depletion in FACS, EdU labeling and replicative histones at both protein and RNA levels (Figures S1A and S2B-S2F). Depleting independently either ASF1a or ASF1b, did not match the double depletion (Figures S1A and S2B-S2F). Since both ASF1 and HIRA in yeast regulate transcription of histone genes ²⁵ and HIRA in mammals is a negative regulator of replicative histones ³³, we also depleted HIRA. However, HIRA depletion did not alter FACS or EdU labeling and did not impact replicative histones at both protein and RNA levels (Figures S1A and S2B-S2F).

We conclude that ASF1 depletion, but not CAF-1 depletion nor HU treatment, modulates the levels of both total RNA and soluble protein corresponding to replicative histone genes. Thus, the impact of ASF1 depletion on replicative histones cannot be reproduced by a chromatin assembly defect or a replication stress.

ASF1 depletion reduces the expression of most annotated replicative histone genes at a transcriptome level during S phase

We compared RNA-seqs from siCtrl- and siASF1-transfected asynchronous cells including spike in controls (Figure 2A). Differential gene expression analysis revealed global transcriptional changes after ASF1 depletion (Figures 2A, S3A and S3B). Pathways associated with cell cycle progression, most notably MYC-driven pathways, ranked among the top downregulated. Instead,

among the top upregulated pathways, tumor necrosis factor alpha (TNF α) signaling and the p53 pathway proved enriched, in line with their roles in cell cycle arrest. Interestingly, the nonreplicative histone gene H1-0, normally reduced in cells with long-term self-renewal ability and tumorigenic potential^{34,35}, was also upregulated. Altogether, these changes are consistent with the reduced proliferation and slow S phase completion observed in ASF1-depleted cells.^{22,24} The noticeable reduction in the expression level of replicative histone genes after ASF1 depletion caught our attention, with replicative histones enriched among the top significantly downregulated genes (Figure 2A and Table S1). To better characterize the effect of ASF1 depletion on gene expression along S phase, we then generated total RNA-seq data from cells synchronized at G1/S arrest (0 hr) by double thymidine block and released until early (2 hrs) and mid S phase (5 hrs) (scheme and FACS Figure 2B). Of note, around half the number of cells in siASF1 condition enter S phase after release as compared to siCtrl condition. For each time point we included spike in controls. Hierarchical clustering of differentially expressed genes after ASF1 depletion at different S phase stages identified six main groups (annotated 1 to 6) (Figures 2C, 2E and S3C): downregulated genes in groups 1, 2 and 3, and upregulated genes in groups 4, 5 and 6 (Table S1). Groups 1 and 2 comprised the top downregulated genes after ASF1 depletion with the strongest changes with S phase progression under control conditions (Figure 2E). Group 1 showed enrichment in genes involved in DNA replication. Group 2 stood out: it exclusively comprised 37 of the 59 replicative histone genes affected by ASF1 depletion among the 66 annotated replicative histone genes with detectable expression. This group 2 showed the largest differences in expression along S phase progression and under conditions of ASF1 depletion (Figures 2D and 2E). Indeed, under control conditions, replicative histone genes displayed their lowest expression levels in G1/S cells and the strongest induction after release

into S phase, progressively peaking from early (2 hrs) to mid S phase (5 hrs). ASF1 depletion led to a striking failure to increase the expression of all these genes after release. Additionally, we compared expression of all replicative histone genes with each other and with non-replicative histone genes (Figures S3D and S3E). We noted that, after ASF1 depletion, ten replicative histone genes, not clustered in Group 2, are also downregulated, and only five are unaffected.

Thus, ASF1 depletion has a strong effect on S phase-dependent genes, among which a large set of the annotated replicative histone genes.

ASF1 depletion increases replicative histones at the level of nascent/newly synthesized RNA

To consider the multiple levels in regulating replicative histone genes ^{5,6}, we first explored ASF1 role at the level of transcription. While NPAT is crucial in regulating the transcription of replicative histone genes ^{36,37}, FLASH has been involved in NPAT localization at HLBs ³⁰. By immunofluorescence, as expected, NPAT foci disappeared in FLASH-depleted cells while present in all the other conditions, and even brighter after ASF1 depletion as for FLASH foci (Figure S4). Thus, HLBs are maintained in ASF1-depleted cells. To analyze the newly transcribed RNAs, we performed 4-Thiouridine-labeled RNA-sequencing (4sU-labeled RNA-seq) in asynchronous cells 48 hrs after siRNA transfection including spike-in controls (experimental scheme Figure 3A). To our surprise, ASF1 depletion led to increased levels of nascent/newly synthesized RNAs for replicative histone genes (Figure 3A). This was surprising given the decrease in their expression observed by RNA-seq and RT-qPCR using total RNA. We compared heatmaps from this 4sU-labeled RNA-seq and the previous total RNA-seq (Figure 2A), using the hierarchical clustering with 6 groups as for the total RNA-seq using synchronized cells (Figure 2C). Strikingly, group 2 which comprises most replicative histone

genes exhibited an opposite behaviour in 4sU-labeled and total RNA-seqs (Figures 3B and 3C). While most replicative histone genes affected by ASF1 depletion showed this peculiar behaviour, this was not the case for non-replicative histone genes (Figure 3C). Comparing total and 4sU-labeled RNA-seqs (Figure 3D), most genes showed the same behaviour in both datasets, including non-replicative histone genes. In sharp contrast, while downregulated in total RNA-seq, the replicative histone genes stood out with a clear upregulation in 4sU-RNA-seq. Of note, in contrast to total RNAs, which steady state levels reflect transcription, processing and decay, the amount of nascent/newly synthesized RNAs depends on transcription but in the case of short genes such as replicative histone genes, also depends on processing. Thus, our data suggest that an increase in nascent/newly synthesized transcripts for the replicative histones after ASF1 depletion corresponds either to a higher transcription or to an accumulation of newly synthesized replicative histone transcripts, possibly because of a processing defect, or both.

In conclusion, while ASF1 depletion led to a decrease in total transcripts corresponding to replicative histones, our latter results showed that when considering nascent/newly synthesized RNAs, their amounts rather than reducing, they even increased. These data prompted us to explore whether ASF1 may impact the 3'-end processing of replicative histone premRNAs.

ASF1 depletion affects the 3'-end processing of replicative histone pre-mRNAs

In metazoans, replicative histone transcripts are not polyadenylated and associated with a unique post-transcriptional regulation. ⁴ The 3'-end processing of replicative histone pre-mRNAs occurs with a cleavage between the stem loop (SL) and the histone downstream element (HDE) to produce mRNAs with the SL and deprived of the sequence downstream the cleavage site and

notably the HDE⁴ (Figure 1A). We performed a metagene analysis for all replicative histones to be able to provide the average change in RNA reads when comparing siCtrl to siAsfl. This plot shows unambiguously a higher fold change in region 3' of the SL when compared to region within the replicative histone gene in both total and 4sU-labeled RNA-seqs (Figure 4A). This is illustrated in individual snapshots from genome browser corresponding to individual genes (Figure S5A). By measuring the fraction of fragments overlapping the cleavage site between the SL and the HDE, we could confirm the presence of a higher fraction of unprocessed pre-mRNAs in both asynchronous total and 4sU RNA-seqs as well as in total RNA-seq from synchronized cells (Figure S5B). Taken together these analyses are consistent with an increase of unprocessed transcripts when ASF1 is depleted.

Disruption of the 3'-end processing of replicative histone pre-mRNAs enables polyadenylation at a distal polyA site ^{38–41} or oligoadenylation when proceeding towards degradation by the RNA exosome. ^{42,43} Here, we found reads from replicative histone transcripts with long stretches of adenines. The number of these reads, hereafter designated as oligo/polyadenylated reads, increased after ASF1 depletion (Figure S5C, left) while the level of adenylated RNAs of other highly expressed genes did not change (Figure S5C, right). This finding further supports an impact of ASF1 depletion on the 3'-end processing of replicative histone RNAs.

To confirm the 3'-end processing defect, we performed RT-qPCR for two different replicative histone genes, H1-4 and H3C14, using primers allowing to amplify only premRNAs/unprocessed transcripts (primers "pre" located downstream the cleavage site) (scheme Figure 4B). By using total RNAs from siRNA-transfected or HU-treated cells (scheme Figure 1B), we found that the amount of pre-mRNAs/unprocessed RNAs significantly increased after siASF1 and siFLASH transfections as compared to siCtrl but not after siCAF-1 transfection or HU treatment (Figure 4B). This argues that ASF1 depletion affects the 3'-end processing of replicative histones, as previously demonstrated for FLASH depletion. ^{26,27} In agreement with the fact that the replicative histones remained unaffected after single depletions (siASF1a or siASF1b alone) or HIRA depletion, we did not detect any increase of unprocessed transcripts under these conditions while SLBP depletion led to some increase (Figure S5D).

Therefore, we conclude that ASF1 depletion affects the 3'-end processing of the replicative histone pre-mRNAs.

DISCUSSION

Here, we discovered a role for the histone chaperone ASF1 in regulating specifically the expression of replicative histone genes. As illustrated in Figure 4C, ASF1 depletion led to increased amount of nascent/newly synthesized replicative histone RNAs while the amount of total RNAs decreased, resulting subsequently in a decrease of replicative histone proteins. Moreover, ASF1 depletion affects the 3'-end processing of replicative histone pre-mRNAs. This is very distinct from CAF-1 depletion which acts solely at the deposition level downstream of ASF1 (Figure 4C). Our data thus argue for a specific role of ASF1 in mammals in controlling the expression of replicative histone genes by regulating their RNA metabolism.

The increase of nascent/newly synthesized replicative histone transcripts in ASF1depleted cells can be due to the accumulation of unprocessed transcripts (still not degraded) or to an increase in transcription of the corresponding genes, or both. We found that the decrease of total replicative histone transcripts reflects a defect of their 3'-end processing and their targeting to degradation, at least in part, via the RNA exosome (preliminary data). The exact cause of this defect remains unknown, and we do not exclude a possible consequence of a transcriptional defect. However, a direct role of ASF1 in the 3'-end processing of replicative histone RNAs is supported by the identification of ASF1 in a screen for factors involved in replicative histone pre-mRNA processing in Drosophila.⁴⁴ The fact that depleting key processing factors specific of replicative histone pre-mRNAs like FLASH and SLBP leads to phenotypes that compared to ASF1 depletion further connects ASF1 to the replicative histone RNA processing. Indeed, FLASH or SLBP depletions, both lead to a decrease in replicative histones, slower S phase progression and ssDNA formation defects in response to replication inhibitors as observed in cells lacking ASF1.⁴⁵ However, ASF1 depletion reduces more severely levels of total RNAs corresponding to replicative histone genes as shown by RT-qPCR (Figure 1E), indicating a higher degradation of the replicative histone RNAs when compared to FLASH- and SLBP-depleted cells. In contrast, the differences between a HU treatment, that affects DNA replication, and siASF1 transfection argue that the impact of ASF1 depletion on replicative histone RNA metabolism is not just a mere consequence of DNA replication slowing down. Future work should dissect further how and where ASF1 intervenes in the RNA metabolism specific of the replicative histone genes.

Previous reports showed that both ASF1 and CAF-1 depletions affect S phase progression due to nucleosome assembly defects during replication. 22,24,46 We should now integrate that ASF1 depletion impacts expression of replicative histone genes which could by itself also contributes to the defect of S phase progression. Of note, arrest in S phase progression upon overexpression of the histone chaperone HIRA had been linked to defect in the expression of replicative histone genes.³³ While at first, these observations had led to propose that HIRA acted as a repressor of replicative histone gene expression, as reported in yeast ^{47,48}, alternative explanations could build on our results. Indeed, overexpression of the HIRA mutant unable to interact with ASF1²⁰ cannot interfere with the expression of replicative histone genes. ³³ Thus, considering our new findings, the difference between overexpression of HIRA wild type and HIRA lacking ASF1 interaction, could reflect the trapping of ASF1 by HIRA, preventing ASF1 to stimulate the replicative histone gene expression. Notably, we did not detect any effect of HIRA depletion on replicative histones arguing against its direct role as a repressor of their expression in human cells. Finally, the histone chaperone nuclear autoantigenic sperm protein (NASP), found together with ASF1 in a multichaperone complex²⁴, protects soluble H3-H4

proteins against degradation but its depletion does not affect the cell cycle ⁴⁹, which is clearly different from ASF1 depletion. More generally, the role of ASF1 in the synthesis of replicative histones offers a different framework for the interpretation of previous observations linked to ASF1 defects. Indeed, most transcriptomic data have been generated from poly(A+) RNAs and usually do not include replicative histone RNAs, and thus several studies probably missed the impact of ASF1 on the expression of replicative histone genes. Notably, the upregulation of ASF1a or ASF1b observed in various cancers ^{14,50} that gives tumoral cells a proliferation advantage, may actually relate to a combined stimulation of both replicative histone synthesis and deposition processes, an aspect under-explored in tumorigenesis. We postulate that fine tuning ASF1 dose and function would thus provide the cell with an ingenious way to prevent imbalance in histone provision. Coupling replicative histone expression to ASF1 availability would represent a "chaperone checkpoint" to control the histone flow during S phase thereby preventing excess of free replicative histones that could be deleterious for the cell.

LIMITATIONS OF THE STUDY

We find a role for ASF1 in the RNA metabolism of replicative histone genes during S phase. However, how cell cycle influences this role, and the exact molecular mechanism remains to be deciphered, including a link between ASF1 and specific components of the 3'-end processing of replicative histone RNAs. Our study also shows that the effect of ASF1 applies broadly to all type of replicative histones from the histone clusters. To examine individually genes in each cluster, it will be interesting to quantify replicative histone RNAs using single molecule RNA FISH and to determine whether a similar role in RNA metabolism could be assigned to other histone chaperones and in particular H2A-H2B chaperones. Finally, following our analysis on cultured cells it would be exciting to explore the function of ASF1 on replicative histone RNA metabolism in other cells, during development, in non-tumoral primary cells, in ESCs and especially in cancer cells with described overexpression of ASF1.

ACKNOWLEDGMENTS

We thank Antoine Coulon and Kyra Borgman for support on RNA analysis. This work was supported by the ERC-2015-ADG-694694 "ChromADICT", the Ligue Nationale contre le Cancer (Equipe labellisée Ligue), ANR-11-LABX-0044_DEEP and ANR-10-IDEX-0001-02 PSL. S.M. was supported by ANR-16-CE11-0028 "REPLICAF" and ERC-2015-ADG-694694 "ChromADICT", A.G. by H2020 Marie Skłodowska-Curie Actions grant agreement 798106 "REPLICHROM4D" and ERC-2015-ADG-694694 "ChromADICT".

AUTHOR CONTRIBUTIONS

Conceptualization, S.M., D.R.-G., G.A.; Investigation, S.M., D.R.-G., A.F. and M.A.K.; Software and Data Curation, A.G. and S.L.; Formal analysis, S.L.; Writing-Original draft, S.M., A.G., D.R.-G. and G.A.; Writing-Review & Editing, D.R.-G., S.L. and G.A.

DECLARATION OF INTERESTS

The authors declare no competing interests.

FIGURE LEGENDS

Figure 1. ASF1 depletion reduces replicative histones at the levels of both protein and total RNA

(A) Scheme for replicative histones genes, their transcription, protein synthesis and incorporation into chromatin. Intron less replicative histone genes in multiple copies are organized in clusters on chromosomes 6 (HIST1) and 1 (HIST2 and HIST3). Their pre-mRNAs are cleaved downstream of a conserved stem loop (SL) and upstream of a purine rich Histone Downstream Element (HDE). Their mRNAs lack polyadenylation in metazoans. After translation, ASF1 interacts with soluble replicative H3-H4 dimers and transfers them to CAF-1 to form nucleosomes on replicated DNA, in a DNA synthesis dependent pathway mainly at the replication fork during S phase. (B) Experimental strategy. We transfected human HeLa cells with siRNA or treated them with HU (0.1 mM). 48 hrs after siRNA transfection or 24 hrs after HU treatment, we added EdU for a 20 mins pulse. We performed FACS, EdU labeling, protein, and total RNA preparation. (C) FACS of cells 48 hrs after siRNA (siCtrl, siASF1, siCAF-1-p60 or siFLASH) or 24 hrs after HU (+HU) treatments or control (-HU). With PI-stained cells for DNA content and flow cytometry, we estimated G1, S and G2/M cells (%). (D) Western blot analysis of chromatin fraction and cytosolic extract from cells 48 hrs after siRNA (siCtrl, siASF1, siCAF-1-p60 or siFLASH) or 24 hrs after HU (+HU) treatments or control (-HU). We used 10 and 20 μ g of extracts and γ -tubulin as loading control. We indicated the fold change average for H3.1/H3.2 and H3.3 (for cytosolic extracts and chromatin fraction) and H3.3:H3.1/H3.2 ratio (for chromatin fraction). (E) RT-qPCR analysis of histone RNA levels. We isolated total RNA from HeLa cells 48 hrs after siRNA (siCtrl, siASF1, siCAF-1-p60 or siFLASH) or 24 hrs after HU (+HU) treatments or control (-HU). We showed four replicative genes

(in black) H2AC20 (encodes H2A type 2-C), H1-4 (encodes H1.4), H4C12 (encodes H4) and H3C14 (encodes H3.2), and the two non-replicative genes (in white) H3-3A and H3-3B (both encode H3.3). The fold change in transcript relative to siCtrl or Control (-HU) corresponds to the mean of three independent biological replicates, error bars show standard deviation. We estimated the fold changes significance with a "two.sided" Student test. P-value legend is ***: <0.001, **: <0.05, NS: >= 0.05. See also Figures S1 and S2.

Figure 2. ASF1 depletion reduces total RNA corresponding to replicative histone genes

(A) (Left top) Scheme for the RNA-seq analysis from asynchronous cells. Hela cells transfected with siRNA (siCtrl or siASF1) and harvested 48 hrs later to prepare total RNA for sequencing. (Left bottom) ASF1 depletion efficiency verified by Western blot analysis on whole cell extract from siCtrl- and siASF1-treated cells. We loaded extracts for the same numbers of cells (1x, 2x and 4x). (Right) Volcano plot illustrating the decrease in expression of replicative histone genes after ASF1 depletion from asynchronous cells. For all the genes expressed in at least 2 samples, we provided statistical significance (y-axis, -log10 of FDR) and difference in total RNA (x-axis, log2 fold change) between siASF1 and siCtrl conditions. We highlighted the top 10 significant replicative histone genes affected, ranked by statistical significance, and indicated the replicative histone genes H4C12 and H3C14 and the non-replicative histone genes H3-3A and H3-3B, analysed by RT-qPCR (Figure 1E). (B) (Left) Scheme for the RNA-seq analysis on synchronized cells. After siRNA (siCtrl or siASF1) on day 1, we synchronized cells with a double thymidine block and harvested them on day 3 at 0 (G1/S), 2 and 5 hrs (S phase) after the second thymidine block release, to prepare and sequence total RNA. (Right) FACS of cell synchronized in the different conditions. (C) Heat map of gene expression in siCtrl and siASF1 at different time points

after synchronization and release into S phase for differentially expressed genes (columns) ordered by hierarchical clustering, including all genes showing significant differences at FDR < 0.05. The color gradient is proportional to each gene expression in each sample, relative to their average across all samples (log2 normalized counts, mean-centred and reduced): from blue (lower than average) to red (higher than average). We indicated the six groups of genes, identified based on hierarchical clustering (top six column clusters). We used replicate 1 (R1) and replicate 2 (R2) experiments. **(D)** Zoom on the heat map from panel (C), focus on group 2 with only replicative histone genes. Color gradient shows relative expression as in (C). **(E)** Expression along S phase in siCtrl (blue) and siASF1 (red) conditions for the six groups defined in panel (C). In each graph, we showed the distribution of the genes in each group based on their relative expression averaged on the two replicates and centred on 0. S phase time are 0 (G1/S), 2 and 5 hrs (S phase) after release from G1/S. Values as in panels (C) and (D). See Figure S3C for Gene ontology (GO) for each group. See also Figure S3 and Table S1.

Figure 3. ASF1 depletion increases nascent/newly synthesized RNA for replicative histones

(A) (Left) Scheme for 4sU-labeled RNA sequencing ⁵¹ 48 hrs after siRNA transfection (siCtrl or siASF1). (**Right**) Relative nascent/newly synthesized RNA level (mean-centred counts, normalized and log2 transformed) of replicative histone genes from 4sU-labeled RNA-seq performed in control condition (siCtrl) and after ASF1 depletion (siASF1). For each replicate (R1 and R2), the box plot shows the distribution of replicative histone genes. (**B**) Heat maps of RNA level from 4sU-labeled RNA-seq (top) and from total RNA-seq (Figure 2A) (bottom). Genes set ordered in six groups as in Figure 2C for differentially expressed genes using total RNA-seq from synchronized cells. Colour gradient shows expression relative to average at the same scale than in Figure 2C (log2 normalized

counts, mean-centred and reduced): from blue (lower than average) to red (higher than average). We showed duplicate (R1 and R2). (C) Zoom on heat maps from panel (B) focusing on Group 2 and heat maps for non-replicative histone genes for comparison. Nascent/newly synthesized RNAs assessed by 4sU-labeled RNA-seq (pulse), for the short replicative histone genes, depend on transcription and processing. Total RNAs assessed by total RNA-seq (steady-state) depend on transcription, processing, and decay. (D) Scatter plot for genes according to their fold changes in total RNA and in 4sU-labeled RNA in asynchronous cells with Group 2 replicative histones in purple and non-replicative histones highlighted in green. Genes on the red line have equal fold changes in both total and 4sU-labeled RNA-seqs. See also Figure S4.

Figure 4. ASF1 depletion affects the 3'-end processing of replicative histone transcripts

(A) Metagene analysis of replicative histone genes of Group 2 in total and 4sU-labeled RNA-seqs. We provided fold change in siASF1 relatively to siCtrl in the replicative histone gene (TSS to SL) and in the region downstream of the SL. Solid and dashed lines correspond to replicates R1 and R2, respectively. (B) (Top) Scheme for replicative histone pre-mRNA and its 3'-end processing, with cleavage downstream of the Stem-Loop (SL) and upstream of the Histone Downstream Element (HDE). For the RT-qPCR, "pre" primers before the SL and downstream of the cleavage site amplify pre-mRNAs/unprocessed transcripts. (Bottom) RT-qPCR for replicative histone pre-mRNAs/unprocessed transcripts with "pre" primers on genes H1-4 and H3C14. We used total RNA from HeLa cells 48 hrs after siRNA (siCtrl, siASF1, siCAF-1-p60 or siFLASH) or 24 hrs after HU (+HU) treatments or control (-HU) (Figure 1B). Fold changes in unprocessed transcript for siASF1, sip60 and siFLASH transfected cells relatively to siCtrl, or for cells treated with HU (+HU) relatively to non-treated cells (-HU) correspond to means for three independent biological replicate

experiments, error bars show standard deviation. Student test provides the significance for siASF1 having a higher fold change than in another condition. P-value legend is ***: < 0.001, **: < 0.01, *: < 0.05, NS: >= 0.05. (C) Model to summarize the impact of CAF-1 and ASF1 depletions on the synthesis and usage of replicative histones during S phase. ASF1 depletion leads to an accumulation of newly synthesized pre-mRNAs/unprocessed transcripts, likely targeted to degradation, and a lack of mature mRNAs due to a 3'-end processing defect (1), leading to reduced levels of soluble replicative histones (2) and ultimately a decrease of nucleosomal replicative histones (3). In contrast, CAF-1 depletion does not affect the replicative histone RNA metabolism (1) but leads to an accumulation of soluble replicative histones (2) most likely due to a defect of usage (histone deposition) reflected by a decrease of nucleosomal replicative histones (3). See also Figure S5 and Table S1.

STAR METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|----------------|---------------------------|
| Antibodies | - | |
| ASF1a | Cell Signaling | Cat#2990 |
| ASF1b | Agrobio | Groth et al ²⁴ |
| H3.1/2 | Active Motif | Cat#61629 |
| H3.3 | Millipore | Cat#09-838 |
| H4 | Abcam | Cat#ab31830 |
| H2B | Abcam | Cat#ab1790 |
| p60 (CAF-1) | Agrobio | Groth et al ²⁴ |
| FLASH | Sigma | Cat#HPA053573 |
| SLBP | Abcam | Cat#ab181972 |
| HIRA | Active Motif | Cat#WC119.2H11 |
| NPAT | Invitrogen | Cat#PA5-66839 |
| γ-tubulin | Sigma | Cat#T5326 |
| Vinculin | Sigma | Cat#V9131 |
| Chemicals, peptides, and recombinant proteins | | |
| Hydroxyurea (HU) | Sigma | Cat#H 8627 |
| Lipofectamine RNAiMAX | Invitrogen | Cat#13778-150 |
| Lipofectamine 2000 | Invitrogen | Cat#11668-019 |
| 4-Thiouridine (4sU) | Sigma | Cat#T4509 |
| Dulbecco's Modified Eagle's Medium (DMEM) | Gibco | Cat#41966 |
| Opti-MEM, Reduced Serum Medium | Gibco | Cat#31985 |
| Vectashield, Antifade Mounting Medium | Vector | Cat#H-1000 |
| | Laboratories | |
| Protein Assay Dye Reagent Concentrate | Bio-Rad | Cat#5000006 |
| SuperSignal [™] West Pico PLUS Chemiluminescent | Thermo Fisher | Cat#34580 |
| | Scientific | 0.1//540707 |
| FXCycle TM PI/RNase solution | Invitrogen | Cat#F10797 |
| RNase-free DNase | | Cat#79254 |
| | Scientific | Cat#AM1907 |
| Protease Inhibitor Cocktail Tablets - Complete, EDTA- free | Roche-Merck | Cat#05056489001 |
| Phosphatase Inhibitor Cocktail Tablets - PhosSTOP | Roche-Merck | Cat#04906837001 |
| Pierce Reversible Stain | Thermo Fisher | Cat#1858784 |
| Critical commercial assays | Ocientine | |
| Click-iT TM Ed.I Alexa Eluor TM 594 Imaging Kit | Invitrogen | Cat#C10339 |
| RNeasy Plus Mini Kit | | Cat#C10339 |
| SuperScript TM III First Strand Synthesis SuperMix | | Cat#11752_050 |
| PowerSYBR Green PCR Master Mix | ARI | Cat#4367659 |
| Denosited data | | |
| PNA and data | ArrovEveree | E MTAP 12501 |
| RIVA-SEY Udia | AnayExpress | <u>E-IVIIAD-12001</u> |
| Raw data, western blots and microscope images | | vdfrrct.1 |

| Human: HeLa ATCC CC-L2 Digonucleoides Cat#D-001810-01 OGUUUACAUGUCGACUAA Dharmacon Cat#D-001810-01 ON-TARGETplus ASF1a siRNA #1 Dharmacon Groth et al ²² OUGAAGAAUUAGGACUCAACUUU Dharmacon Groth et al ²² ON-TARGETplus ASF1a siRNA #2 Dharmacon Groth et al ²² CUGAAAUUCCGUAAGUUU Dharmacon Groth et al ²² ON-TARGETplus ASF1a siRNA #3 (3'UTR) Dharmacon Groth et al ²² CCGACGACUUCCGUACUUU Darmacon Groth et al ²² ON-TARGETplus ASF1b siRNA #2 Dharmacon Groth et al ²² CCGACGACUGACUUCACUUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLBS siRNA #3 (3'UTR) Dharmacon Mejivang et al ⁴⁵ CCGCAAGAGUACAUUACCUUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLBS siRNA Dharmacon Mejivang et al ⁴⁵ CCGUGAGGUUCAAUGUCUUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLBS siRNA Dharmacon Ray-Gallet et al ⁵³ GGUGUGCUUCAAUGUCAUUU Dharmacon Ray-Gallet et al ⁵⁴ | Experimental model: Cell line | | | | |
|--|---|-----------|------------------------------|--|--|
| Oligonucleotides Cat#D-001810-01 UGGUUUACAUGUCGACUAA Dharmacon Cat#D-001810-01 QGAUAACAUGUCGACUAA Dharmacon Groth et al ²² QUGANGANACGAUCAGUUU Dharmacon Groth et al ²² GAGACAAAUUACGAUCAGUUU Dharmacon Groth et al ²² QAAAUACGAUCAGUUU Dharmacon Groth et al ²² ON-TARGETplus ASF1a siRNA #3 (3'UTR) Dharmacon Groth et al ²² CACCAAAUUCCAUCAACCUUU Dharmacon Groth et al ²² CAACCAGUACUCAACCCUUG Dharmacon Groth et al ²² CGGACGACCUGGAGUGGAAUU Dharmacon Groth et al ²² CGGACGACCUGAGUGGAAUU Dharmacon This paper CCUUGAGUUCAAUUGAUCUU Dharmacon Mejivang et al ⁴⁵ CCCGAAGGAUGAAGAAAUAUU Dharmacon Mejivang et al ⁴⁵ CCCGCAGUUUCCAAUUUCUAGAAUUUU Dharmacon Mejivang et al ⁴⁵ CCCGGAGGACUUUCAAUUUCUAGAAUUUUU Dharmacon Mejivang et al ⁴⁵ CCCGCAGGACUUUCAAUUUCUAGAAUUUUU Dharmacon Mejivang et al ⁴⁵ CCCCGAGACUGAAUUUUCUAGAAUUUUU Dharmacon Rejvang et al ⁴⁵ | Human: HeLa | ATCC | CC-L2 | | |
| ON-TARGETplus Non-targeting control siRNA Dharmacon Cat#D-001810-01 UGGUUUACAUGUCGACUAA Diarmacon Groth et al ²² OU-TARGETplus ASF1a siRNA #1 Dharmacon Groth et al ²² ON-TARGETplus ASF1a siRNA #2 Dharmacon Groth et al ²² CAGACAGAUUAAGGGAAUU Dharmacon Groth et al ²² CAGACAGAUUCCGUAAGUAUU Dharmacon Groth et al ²² CACCAGAUUACCUCAACCUUU Dharmacon Groth et al ²² CAACGAGUAUCCUCAACCUUU Dharmacon Groth et al ²² ON-TARGETplus ASF1b siRNA #3 (3'UTR) Dharmacon Groth et al ²² CGGACGACAUUGAUCUGAUUU Dharmacon Mejivang et al ⁴⁵ CCUUGAUUCCUGAAUUU Dharmacon Mejivang et al ⁴⁵ CCUUGAUUGCAUUGAAUUU Dharmacon Mejivang et al ⁴⁵ CGALGACAUUGAUUUCCAAGAAUUU Dharmacon Mejivang et al ⁴⁵ GGAUACACUCAUUGUCAUUUUU Dharmacon Rey-Gallet et al ⁵³ GGAUACACAUCUCAUCAUUUUU Dharmacon Rey-Gallet et al ⁵³ GGAUACACAACAGAAGACA Sigma This paper ATTRGETplus SPO FA-1 siRNA Dharmacon | Oligonucleotides | | | | |
| UGGUUUACAUGUCGACUAA Diarmacon Groth et al ²² ON-TARGETPIUS ASF1a SIRNA #1 Dharmacon Groth et al ²² ON-TARGETPIUS ASF1a SIRNA #2 Dharmacon Groth et al ²² ON-TARGETPIUS ASF1a SIRNA #3 (3'UTR) Dharmacon This paper CCUGGAAUUCCGUAAGUUU Dharmacon Groth et al ²² CAACCAGACUACCOUUL Dharmacon Groth et al ²² CAACAGAGUACCUAACCCUUU Dharmacon Groth et al ²² CGGACAGACUUCGAAUUCUU Dharmacon Groth et al ²² ON-TARGETPIUS ASF1b SIRNA #3 (3'UTR) Dharmacon This paper CCUUGAGUACCAUUGAAUCUU Dharmacon Mejivang et al ⁴⁵ CGGACGAGUACAAUUUGCAACAGAAUU Dharmacon Mejivang et al ⁴⁵ CGGAUGACAUUUGCAAGAAUUU Dharmacon Mejivang et al ⁴⁵ CGGUGUGCAAUUUUCAAGAAUUU Dharmacon Rejvang et al ⁴⁵ CGGUCUCAUUUGCAUGUUUU Dharmacon Rejvang et al ⁴⁵ CGGUAUGCAUGUUUUCAUUUUU Dharmacon Rejvang et al ⁴⁵ CGUGGGCUUCAAUUUUCAGAAUUUUUU Dharmacon Rejvang et al ⁴⁵ CGUGGGCAACAGAUAGACA ConcogGaUuuUUCAUUUUU Dharmacon Rejvang et al ⁵³ CGC | ON-TARGETplus Non-targeting control siRNA | Dharmacon | Cat#D-001810-01 | | |
| ON-TARGETplus ASF1a siRNA #1 Dharmacon Groth et al ²² GUGAAGAAUACGAUCAAGUUU ON-TARGETplus ASF1a siRNA #2 Dharmacon Groth et al ²² GAGACAGAAUUAAGGGAAUU ON-TARGETplus ASF1a siRNA #3 (3'UTR) Dharmacon Groth et al ²² CCUGAAAUUCCGUAACCUUU Dharmacon Groth et al ²² CAACGACCUGAACCUUU ON-TARGETplus ASF1b siRNA #1 Dharmacon Groth et al ²² CCAACGACUGACCUUGAAUU ON-TARGETplus ASF1b siRNA #2 Dharmacon Groth et al ²² CCCGACCACCUGAAUUACUU ON-TARGETplus ASF1b siRNA #3 (3'UTR) Dharmacon This paper CCCUUCAGUACAUUACAUUU ON-TARGETplus SLASF siRNA Dharmacon Mejivang et al ⁴⁵ CCGACGACACAGAAGAUUU ON-TARGETplus SLASF siRNA Dharmacon Mejivang et al ⁴⁵ CCUUGAQUUCCAUCGAGAAUUU Dharmacon Mejivang et al ⁴⁵ CCUUCAUUCAUGUUUU ON-TARGETplus SLASF siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUAACAUGUCCAUCGAACAAGAAGAC Dharmacon Ray-Gallet et al ⁵³ GGAUACAUUGCAAGAAGAAGAC Primer H2AC20 Reverse Sigma This paper GCTCGGACAACAAGAAGAAC Sigma Primer H3C12 Reverse <t< td=""><td>UGGUUUACAUGUCGACUAA</td><td></td><td></td></t<> | UGGUUUACAUGUCGACUAA | | | | |
| GUGAAGAAUACGAUCAAGUUU International Construction of the second consecond construction of the second consecond | ON-TARGETplus ASF1a siRNA #1 | Dharmacon | Groth et al ²² | | |
| ON-TARGETplus ASF1a siRNA #2 Dharmacon Groth et al ²² ON-TARGETplus ASF1a siRNA #3 (3'UTR) Dharmacon This paper CCUGAAAUUCCGUAAGUAUU Dharmacon Groth et al ²² CAGACAGAUCCUCAACCUUU Dharmacon Groth et al ²² CGGACGACCUGAACUCUAACCUUU Dharmacon Groth et al ²² CGGACGACCUGAACUGAAUU Dharmacon This paper CUUGAGUACCAUGAAUUAU Dharmacon This paper CCUUGAQUACCAUGAUCUU Dharmacon Mejivang et al ⁴⁵ CCCGCAAGGAGUACAAUAUU Dharmacon Mejivang et al ⁴⁵ CCGCAGAGAGUACAAUAUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLBP siRNA Dharmacon Polo et al ⁵² CGUGUGGCUUUCAAUGUUUU ON-TARGETplus PARA SiRNA Dharmacon Ray-Gallet et al ⁵³ GGAUAACACUGUCGUCAUC Dharmacon Ray-Gallet et al ⁵³ ON-TARGETplus PARA SiRNA Dharmacon Ray-Gallet et al ⁵³ GGAUAACACUGUCGUCAUC Sigma This paper Primer H2AC20 Forward Sigma This paper GCTGGGACAACAAGAAGAC Sigma This paper Primer H3C12 Reverse Sigma This pap | GUGAAGAAUACGAUCAAGUUU | | | | |
| GAGACAGAAUUAAGGGAAAUU Dharmacon This paper CUGAAAUUCCGUAAGUAUU Dharmacon Groth et al ²² CAACGAGUACCUCAACCCUUU Dharmacon Groth et al ²² ON-TARGETplus ASF1b sIRNA #3 (3'UTR) Dharmacon Groth et al ²² ON-TARGETplus ASF1b sIRNA #3 (3'UTR) Dharmacon This paper CUUGAGUACCUCAAUGAUCUU Dharmacon This paper ON-TARGETplus ASF1b sIRNA #3 (3'UTR) Dharmacon Mejlvang et al ⁴⁵ CGGACGAGUACAGAAAUUU Dharmacon Mejlvang et al ⁴⁵ CGGAUGUGAAGAAAUUU Dharmacon Mejlvang et al ⁴⁵ CGGAUGUGAUUUGAAGAAAUUU Dharmacon Pol et al ⁵² CGCUUGCAAGAAAUUUUUU CGCUUGCAAGAAAUUUUUUU Pol et al ⁵² ON-TARGETplus JIRA siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUGUGCAUGUCAAGAAAUU Dharmacon Ray-Gallet et al ⁵³ ON-TARGETplus JIRA siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUGUGCAUGUCAAGAAGAC Sigma This paper Primer H2AC20 Forward Sigma This paper GCTCGGGACACAAGAGAGAC Sigma This paper Primer H4C12 Forward Sigma This paper <td>ON-TARGETplus ASF1a siRNA #2</td> <td>Dharmacon</td> <td>Groth et al ²²</td> | ON-TARGETplus ASF1a siRNA #2 | Dharmacon | Groth et al ²² | | |
| ON-TARGETplus ASF1a sIRNA #3 (3'UTR)DharmaconThis paperCCUGAAUUUCCGUAAGUAUUDharmaconGroth et al 22CACCAGUUCCACCUUAACUUUDharmaconGroth et al 22CGGACGACCUGAGUGGAAUUDharmaconGroth et al 22CGGACGACCUGAGUGCAUUUDharmaconThis paperCUUGAGUACCAUUGAUCUUDharmaconMejlvang et al 45CGCACGACGUGGAAUUUDharmaconMejlvang et al 45CGCAAGAGUUGAUCUUUDharmaconMejlvang et al 45CGCAAGAGUUGAAAUAUUDharmaconMejlvang et al 45CGCUUGAGUUUUGCAAGAAAUUUDharmaconPolo et al 52CGCUUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al 53CGGUUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al 53CGGUUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al 53CGGACAACAAGAAGACCSigmaThis paperPrimer H2AC20 ReverseSigmaThis paperATTIGCTTTIGGCTTIGGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 ReverseSigmaThis paperCAACCACCGAACAGCGTAGAGSigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperTCAACCAACAGCGCCAASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCAACCACCGAACCAGCTTTTACTGSigmaThis paperPrimer H3C14-pre ForwardSigmaRuepp et al 54CCACCACAACAGCGCCAASigmaRuepp et al 54Primer H3C14-pre ForwardSig | GAGACAGAAUUAAGGGAAAUU | | | | |
| CCUGAAAUUCCGUAAGUAUU Dharmacon Groth et al ²² CAACGAGUACCUCAACCCUUU Dharmacon Groth et al ²² CGAACGAGUACCUGAACCUUU Dharmacon Groth et al ²² CGAACGACUGGAAUU Dharmacon Groth et al ²² ON-TARGETplus ASF1b siRNA #3 (3'UTR) Dharmacon This paper CUUGAGUACCAUUGAUCUU Dharmacon Meijvang et al ⁴⁵ ON-TARGETplus SLBS siRNA Dharmacon Meijvang et al ⁴⁵ CGGUGUGAUQAAGAAAUUU Dharmacon Meijvang et al ⁴⁵ CGAUGUGAUUUGCAAGAAAUUU Dharmacon Pole et al ⁵² ON-TARGETplus BLBP siRNA Dharmacon Pole et al ⁵² GGAUGUGAUUUGCAAGAAUUUUU Dharmacon Ray-Gallet et al ⁵³ ON-TARGETplus BLBA siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUGUCGUUCAAGAAGAGAC Sigma This paper GGTCGGGCAACACGAGAAGAC Sigma This paper GTCGGGGACAACAGAAGAGAC Sigma This paper GTCGGGGACAACAGAAGAGAGAC Sigma This paper Primer H222 Proward Sigma This paper GTCGGGGACAACAGGACTGC Sigma This paper Primer H14 Pror | ON-TARGETplus ASF1a siRNA #3 (3'UTR) | Dharmacon | This paper | | |
| ON-TARGETplus ASF1b siRNA #1DharmaconGroth et al 22ON-TARGETplus ASF1b siRNA #2DharmaconGroth et al 22ON-TARGETplus ASF1b siRNA #2DharmaconThis paperCCUUGAGUACCUCAAUGAUCUUDharmaconThis paperCCUUGAGUACCAUUGAUCUUDharmaconMejlvang et al 45CCGCAAGGAUGAAGAAAUAUUDharmaconMejlvang et al 45ON-TARGETplus SLBP siRNADharmaconMejlvang et al 45GGAUGUAGUAUUGAGAAUUUDharmaconPolo et al 52ON-TARGETplus JLBP siRNADharmaconPolo et al 52GCGUGUGGUUUCAAUGUUUUDharmaconRay-Gallet et al 53ON-TARGETplus HIRA siRNADharmaconRay-Gallet et al 53GGAUGUACUCAAGAAUUUDharmaconRay-Gallet et al 53ON-TARGETplus HIRA siRNADharmaconRay-Gallet et al 53GGAUGUACUCAAGAAGAAGACSigmaThis paperPrimer H2AC20 ForwardSigmaThis paperGTCGGGACAACAAGAAGAGCSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTCCACCGCAAACCGTAGAGSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperCAACCACCGAACAGCACTGCSigmaThis paperPrimer H1-4 pre ForwardSigmaThis paperCTAGTGCAACAGCTTTAGTASigmaThis paperPrimer H3-14 PeverseSigmaThis paperACGTGGCAACACGCTTTTACTGSigmaRuepp et al 54Primer H3C14 PreverseSigmaRuepp et al 54CCACCACCGTATCGAACGCTTTSigmaRuepp et al 54 <td< td=""><td>CCUGAAAUUCCGUAAGUAUU</td><td></td><td></td></td<> | CCUGAAAUUCCGUAAGUAUU | | | | |
| CAACGAGUACCUCUCAACCCUUU Dharmacon Groth et al ²² CGGACGACCUGGAGUGGAAUU Dharmacon This paper CCUUGAGUACCAUUGAUCUU Dharmacon Mejivang et al ⁴⁵ CCGCAAGGAUGAAGAAUUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLPS IRNA Dharmacon Mejivang et al ⁴⁵ CCGCAAGGAUGAGAAUUU Dharmacon Mejivang et al ⁴⁵ ON-TARGETplus SLPS IRNA Dharmacon Mejivang et al ⁴⁵ GGAUGACACUUCCAAUGUUUU Dharmacon Ray-Gallet et al ⁵³ ON-TARGETplus HIRA SIRNA Dharmacon Ray-Gallet et al ⁵³ GGAUAACCUGUCGUCAUC Dharmacon Ray-Gallet et al ⁵³ Primer H2AC20 Forward Sigma This paper GCTCGGACAACAAGAGACAC Sigma This paper ATTTGCTTTGGCTTTGTGG Sigma This paper Primer H2C12 Forward Sigma This paper CACCACCGAACATATCCAG Sigma This paper CTAACCACCGAACTTATCCAG Sigma This paper CTAACCACCGACATATCCAG Sigma This paper CTAACCACCGACACTTACCAG Sigma This paper CTAACCACCGACACTTACCAGA Sigma< | ON-TARGETplus ASF1b siRNA #1 | Dharmacon | Groth et al ²² | | |
| ON-TARGETplus ASF1b siRNA#2 Dharmacon Groth et al ²² CGGACGACCUGGAQUGGAAUU Dharmacon This paper CUUGAGUACCAUUGAUCUU Dharmacon Mejlvang et al ⁴⁵ ON-TARGETplus SLBH siRNA Dharmacon Mejlvang et al ⁴⁵ GCGCAAGGAUGAAGAAUAUU Dharmacon Mejlvang et al ⁴⁵ ON-TARGETplus SLBF siRNA Dharmacon Mejlvang et al ⁴⁵ GCGUGUGCUUUCAAGAAUUU Dharmacon Polo et al ⁵² GCAUGUGCACUUUCAAUGUUUU Dharmacon Ray-Gallet et al ⁵³ ON-TARGETplus HRA siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUGAGCAUUCAAUGUUUU Dharmacon Ray-Gallet et al ⁵³ GGAUGACACUGACAACAAGAAGAC Sigma This paper ON-TARGETplus HRA siRNA Dharmacon Ray-Gallet et al ⁵³ GGAUGACACUGACAACAAGAAGAC Sigma This paper Primer H4C12 Forward Sigma This paper TACTGCGCGACACAAGACAGAC Sigma This paper TACTGCGCGACACACAGCAGCAGAGAGA Sigma This paper TACTGCGCGACACACAGCAGCGCAA Sigma This paper TCACACACGGACACCAGCAGCAGAGAG Sigma This paper | CAACGAGUACCUCAACCCUUU | | | | |
| CogaCGACCUGGAGUGGAAUUDharmaconThis paperCCUUGAGUACCAUUGAUCUUDharmaconMejlvang et al ⁴⁵ CCCUAGGAUGAAGAAAUUUDharmaconMejlvang et al ⁴⁵ CCGCAAGGAUGAAGAAAUUUDharmaconMejlvang et al ⁴⁵ ON-TARGETplus SLBP siRNADharmaconPolo et al ⁵² GGAUGUGGUUUCAAUGUUUDharmaconPolo et al ⁵² GCGUGUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al ⁵³ GGAUAACACUGUCGUCAUCDharmaconRay-Gallet et al ⁵³ Primer H2AC20 ForwardSigmaThis paperGCTCGGGACAACAGAGAGACSigmaThis paperPrimer H4C12 ForwardSigmaThis paperATTIGCTTTIGGCTTTGTGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperCAACCACGCGAACATATCCAGSigmaThis paperPrimer H4-C12 ForwardSigmaThis paperCAACCACCGAACCGTAGAGSigmaThis paperCAACCACGCAACAGCTTTGTGGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperCTAACCAGCGCAACAGCTTTAGTASigmaThis paperPrimer H1-4 ForwardSigmaThis paperCTAACCAGCCCGCCAASigmaThis paperAGGCGGCAACAGCTTTAGTASigmaRuepp et al ⁵⁴ Primer H3C14 ForwardSigmaRuepp et al ⁵⁴ GCGCGCGGTCAACGCTTTTCCSigmaRuepp et al ⁵⁴ Primer H3C14 Per ServardSigmaThis paperAGACCGGTCAACGCTTTCCSigmaRuepp et al ⁵⁴ Primer H3C14 ForwardSigmaRuepp et al ⁵⁴ < | ON-TARGETplus ASF1b siRNA #2 | Dharmacon | Groth et al ²² | | |
| DN-TARGE I plus AS-T0 SiRNA #3 (3 UTR)DharmaconThis paperCCUUGAGUACCAUUGAUCUUDharmaconMejlvang et al ⁴⁵ CCCUGAGGAUGAAGAAAUAUUDharmaconMejlvang et al ⁴⁵ ON-TARGETplus SLPP siRNADharmaconPolo et al ⁵² GCAUGGCUUUCAAUGUUUUDharmaconPolo et al ⁵² ON-TARGETplus SDCAF-1 siRNADharmaconRay-Gallet et al ⁵³ GGAUGACUUCAUGUGUCAUCDharmaconRay-Gallet et al ⁵³ ON-TARGETplus HIRA siRNADharmaconRay-Gallet et al ⁵³ GGAUAACACUGUGUCAUCSigmaThis paperPrimer H2AC20 ForwardSigmaThis paperGCTCGGGACAACAAGAAGACSigmaThis paperATTTGCTTITGGTGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperCAACCACCGAACCGTAGAGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperTCAACCAGCGAACACCTTTAGTASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperCTAAGCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperCTAAGCAAAGACCGCCAASigmaThis paperPrimer H3C14 ForwardSigmaRuepp et al ⁵⁴ CCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14 Pre reverseSigmaRuepp et al ⁵⁴ CAGCGCGGTCAACAGCTTCTCCSigmaThis paperPrimer H3C14 PreverseSigmaThis paperCAAGCGGTACAGCTTTTCCSigmaR | | Dhamman | | | |
| DebugsdoutsAdoutsAdoutsAdoutsAdoutsDharmaconMeijvang et al 45CCGCAAGGAUGAAGAAAUAUUDharmaconMeijvang et al 45ON-TARGETplus SLBP siRNADharmaconPolo et al 52GGAUGUGAUUUGCAAGAAAUUDharmaconPolo et al 52ON-TARGETplus p60 CAF-1 siRNADharmaconRay-Gallet et al 53GGAUACACUGUCGUCAUCDharmaconRay-Gallet et al 53ON-TARGETplus p60 CAF-1 siRNADharmaconRay-Gallet et al 53GGAUAACACUGUCGUCAUCSigmaThis paperPrimer H2AC20 ForwardSigmaThis paperGCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2C12 ReverseSigmaThis paperATTTGCTTTGGTGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTACTGCGCGACACAACAACGAGAGAGSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 ProrestSigmaThis paperCTAACCAAAGACCGCCAASigmaThis paperPrimer H1-4 pre ReverseSigmaThis paperATAGGCAACAGCTTTTACTGSigmaRuepp et al 54Primer H3C14 ForwardSigmaRuepp et al 54CACGCGGTCAACGCTTCTSigmaRuepp et al 54Primer H3C14 pre ForwardSigmaRuepp et al 54CAGCGCGGTCAACGCTTTCCSigmaThis paperPrimer H3C14 pre rowardSigmaThis paperPrimer H3C14 pre rowardSigmaThis pa | ON-TARGETPIUS ASFTD SIRNA #3 (3'0TR) | Dnarmacon | i nis paper | | |
| ON-TARGE TPINSTERSDiamaconIntegrang et al. **ON-TARGETPIUS SLEP SIRNADharmaconMejivang et al. **GGAUGAQAUUGCAAGAAAUUUDharmaconPolo et al. 52ON-TARGETPIUS 960 CAF-1 siRNADharmaconPolo et al. 52GCGUGUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al. 53GGAUAACCUGUCQUCAUCPrimer H2AC20 ForwardSigmaThis paperPrimer H2AC20 ReverseSigmaThis paperATTTGCTTTTGGCTTTGTGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTACTGCGCGACAACCAGCGCAGASigmaThis paperPrimer H4C12 ReverseSigmaThis paperCAACCACCGGAAACCGTAGAGSigmaThis paperPrimer H1-4: ForwardSigmaThis paperTTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4: ForwardSigmaThis paperCTAAACCAACGCTATAGCASigmaThis paperPrimer H1-4: PreverseSigmaThis paperCTAAACCAAGCCTTTAGTASigmaThis paperPrimer H1-4: PreverseSigmaThis paperCTAAACCAAAGACCGCCCAASigmaThis paperPrimer H3C14: ForwardSigmaRuepp et al. 54Primer H3C14: Pre ForwardSigmaRuepp et al. 54GCCGCCGGTCGACTTSigmaRuepp et al. 54Primer H3C14: Pre ForwardSigmaRuepp et al. 54Primer H3C14: ReverseSigmaRuepp et al. 54CAACGCGTACAGCTTTTGCPrimer H3C14: Pre ForwardSigmaPrimer H3C14: ReverseSigma <td></td> <td>Dharmacon</td> <td>Moilyang of al 45</td> | | Dharmacon | Moilyang of al 45 | | |
| DOUGNACIONACIONACIONACIONALDescriptionMejlvang et al 45GGAUGUGAUUUGCAAGAAAUUDharmaconPolo et al 52ON-TARGETplus p60 CAF-1 siRNADharmaconPolo et al 52GCGUGUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al 53GGAUAACACUGUCGUCAUCSigmaThis paperPrimer H2AC20 ForwardSigmaThis paperGCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 ReverseSigmaThis paperATTTGCTTTGGCTTTGTGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTACTGCGCGACAATATCCAGSigmaThis paperPrimer H4-12 ForwardSigmaThis paperCAACCACCGAACCGTAGAGGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperTCCAACACGGCAACAGCTTAGTASigmaThis paperPrimer H1-4 pre ForwardSigmaThis paperCTAACCACAAGACGCCAASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCTAACCACGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperACTAGTGCAACAGCTCTTTACTGSigmaRuepp et al 54Primer H3C14 ReverseSigmaRuepp et al 54GCGCGCGGTACAGCTTTSigmaRuepp et al 54Primer H3C14-pre ForwardSigmaRuepp et al 54CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C14 Pre ReverseSigmaRuepp et al 54CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C1 Forward | | Dhannacon | Mejivang et al | | |
| On Micourg of CalDiamage of CalON-TARGETplus p60 CAF-1 siRNA GCGUGUGGCUUUCAAUGUUUUDharmaconPolo et al 52ON-TARGETplus HIRA siRNA GGAUAACACUGUCGUCAUCDharmaconRay-Gallet et al 53Primer H2AC20 Forward GCTCGGGACAACAAGAAGACASigmaThis paperPrimer H2AC20 Reverse ATTTGCTTTGGCTTTGGCTTGGGSigmaThis paperPrimer H2AC20 Reverse ACTGCGCGACAACAAGAAGACASigmaThis paperPrimer H4C12 Forward TACTGCGCGACAACAGTGCGGAGACAAGAGAGAGASigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Forward Primer H1-4 Pre Forward CTAAACCAAGAGCCCCAASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAGAGCCCCAASigmaThis paperPrimer H1-4-pre Forward GCTGGCAACAGCTCTTTACTGSigmaThis paperPrimer H3C14 Reverse GCCGCGGTCGACTTSigmaRuepp et al 54GCGCCGGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward GCCGCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACAGCTCTTCCSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACAGCTCTTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTCTTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTCTTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTAGCGTTTSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTAGAGCTCTTSigmaThi | ON-TARGET nus SI BP siRNA | Dharmacon | Meilvang et al ⁴⁵ | | |
| ON-TARGETplus p60 CAF-1 siRNA GCGUGUGGCUUUCAUGUUUUDharmaconPolo et al 52ON-TARGETplus HIRA siRNA GGAUAACACUGUCGUCAUCDharmaconRay-Gallet et al 53Primer H2AC20 Forward GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 Forward GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 Reverse ATTTGCTTTTGGCTTTGTGGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACAACCGTAGAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACCGTAGAGSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperAGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre Forward CTAAACCGCCAAASigmaThis paperPrimer H1-4-pre Reverse AGGCGGCAACAGCTCTTTACTGSigmaThis paperPrimer H3C14 Forward GCTGGTAACCCGTGGTTTGGGSigmaRuepp et al 54Primer H3C14 Pre Forward CCAGCGGCGCAACAGCTCTTTSigmaRuepp et al 54Primer H3C14 pre Reverse CCAGCGGTGACTTSigmaRuepp et al 54Primer H3C14 pre Reverse CAAGCGGTCAACGCTCTTCCSigmaRuepp et al 54Primer H3C14 pre Reverse CCAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14 pre Reverse CCAGCGCGTACAGCTTCTCCSigmaThis paperPrimer H3C14 pre Reverse CCAGCGCGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C14 pre Reverse CCAGCGCGCGTAACAGCTCTTCCSigmaThis pape | GGAUGUGAUUUGCAAGAAAUU | Dhannacon | mejivang et al | | |
| GCGUGUGGCUUUCAAUGUUUUDharmaconRay-Gallet et al 53OMATARGETPIUs HIRA SIRNA GGAUAACACUGUCAUCDharmaconRay-Gallet et al 53Primer H2AC20 Forward GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 Reverse ATTTGCTTTTGGTTTGGTGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACCGTAGAGSigmaThis paperPrimer H14 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACCGCCAASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Forward CTGGTAAGCCTGTGTTTTACTGSigmaThis paperPrimer H3C14 Forward GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14 Proward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTCSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACACGCTTCTCCSigmaThis paperPrimer H3C14-pre Forward TTCCATCGTATCCAAAAGGTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGGTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAAGGT | ON-TARGETplus p60 CAF-1 siRNA | Dharmacon | Polo et al ⁵² | | |
| ON-TARGETplus HIRA siRNA GGAUAACACUGUCGUCAUCDharmaconRay-Gallet et al 53Primer H2AC20 Forward GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 Reverse ATTIGCTTITGCTTTGGGTSigmaThis paperATTIGCTTTGCGCGACAACAAGAAGACSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACAGTGCGSigmaThis paperPrimer H14 Forward TTCAACATGTCCGAAACCGTCGAACCGCSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAACCGCCAACGCSigmaThis paperPrimer H1-4 Forward TTCAACCAACAGCGCCAASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAGAGCCGCCAASigmaThis paperPrimer H1-4-pre Forward CTGGTAAGCCTGTGTTTAGTASigmaThis paperPrimer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14 Proward GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14Pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre Reverse CAGCGCCGCGTTATCCAAAAGGTCSigmaThis paperPrimer H3C14pre Reverse CAGCGCCGCGTTATCCAAAAGGTCSigmaThis paperPrimer H3C14pre Reverse CAGCGCCGCGTTATCCAAAAGGTC | GCGUGUGGCUUUCAAUGUUUU | | | | |
| GGAUAACACUGUCGUCAUCImage: Constraint of the second sec | ON-TARGETplus HIRA siRNA | Dharmacon | Ray-Gallet et al 53 | | |
| Primer H2AC20 Forward GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 Reverse ATTTGCTTTTGGCTTTGTGGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAACACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTACTGSigmaThis paperPrimer H3C14 Forward GCCGCCGGTCAGCATTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TCCATCGATATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGATAGCAGCTTCTCCSigmaRuepp et al ⁵⁴ Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14-pre Reverse CAAGCGGTTATCCAAAAGGTCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCCAAAAGGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCGGTGAAAGGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGGCGCGGTGAAAGGTAGTTSi | GGAUAACAĊUGUCGUCAUC | | , | | |
| GCTCGGGACAACAAGAAGACSigmaThis paperPrimer H2AC20 ReverseSigmaThis paperATTTGCTTTTGGCTTTGTGGSigmaThis paperPrimer H4C12 ForwardSigmaThis paperTACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 ReverseSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperTTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 ReverseSigmaThis paperAGGCGGCAACAGCTTAGTASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperATAGTGCAACAGCTCTTTTACTGSigmaRuepp et al ⁵⁴ Primer H3C14 ForwardSigmaRuepp et al ⁵⁴ GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre ForwardSigmaRuepp et al ⁵⁴ TCCATCGTATCCAAAGGCTCTTCCSigmaRuepp et al ⁵⁴ Primer H3C1 ForwardSigmaThis paperAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGCCGCGTTATCCAAAGGACTCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGCCGCGTTATCCAGAAGGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGCGCGCGCGTAGAAGGTAGTTSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAG | Primer H2AC20 Forward | Sigma | This paper | | |
| Primer H2AC20 Reverse ATTTGCTTTTGCGTTIGTGGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACCGTAGAGSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4 reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTACTGSigmaThis paperPrimer H3C14 Reverse GCCGGCGCGACCACTTSigmaRuepp et al ⁵⁴ Primer H3C14 Reverse GCCGCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al ⁵⁴ Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C1 Forward AGATCCGCCGTTATCCAAAGGCTCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCCAAAGGCTCSigmaThis paperPrimer H3C1 Reverse CAGCCGCTGTATCCAAAGGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGCCGCTGTACAAGAGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGCCGCGTTATCCAAAGGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGCCGCGTTATCAAAGGTAGTTSigmaThis pape | GCTCGGGACAACAAGAAGAC | - | | | |
| ATTTGCTTTTGCCTTTGTGGSigmaThis paperPrimer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAGACCGTCCAASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTTTTAGTASigmaThis paperPrimer H3-4-pre Reverse ATAGTGCAACAGCCTGTTTTACTGSigmaRuepp et al ⁵⁴ Primer H3C14 Forward GCCGGCGGCGACGTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward CCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al ⁵⁴ Primer H3C1 Forward AGATCCGCCGTTATCCAAAGGCTCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCCAGAAGTCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCCGCGTGAAAGGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGCCGCGTTATCCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCCGCTGAAAGGTAGTTSigmaThis paper | Primer H2AC20 Reverse | Sigma | This paper | | |
| Primer H4C12 Forward TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 Reverse CAACCACGAAACCGTAGAGSigmaThis paperPrimer H1-4 Forward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre Forward CTAAACCAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTACTGSigmaThis paperPrimer H3-4-pre Reverse ATAGTGCAACAGCTCTTTACTGSigmaThis paperPrimer H3-4-pre Reverse GCTGGTAAGCCTGTGTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14 Forward GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14 Preverse GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCGCGCTAACAGCTCTTCCSigmaThis paperPrimer H3C1 Reverse CAGCGCGCTAACAGCTCTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCGCCGTTATCAGAAGTCSigmaThis paper | ATTTGCTTTTGGCTTTGTGG | | | | |
| TACTGCGCGACAATATCCAGSigmaThis paperPrimer H4C12 ReverseSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperTTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 ReverseSigmaThis paperAGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCTAAACCAAGACCGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperATAGTGCAACAGCTCTTTACTGSigmaRuepp et al ⁵⁴ Primer H3C14 ForwardSigmaSigmaRuepp et al ⁵⁴ GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14-pre ForwardSigmaRuepp et al ⁵⁴ CCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre ReverseSigmaRuepp et al ⁵⁴ CAGCGGTGGTACAGCTCTTCCSigmaRuepp et al ⁵⁴ Primer H3C14-pre ReverseSigmaRuepp et al ⁵⁴ CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGGCGCGGAAGGTACAGTTSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGGCGCGGAAGGTAGTTSigmaThis paper | Primer H4C12 Forward | Sigma | This paper | | |
| Primer H4C12 ReverseSigmaThis paperCAACCACCGAAACCGTAGAGSigmaThis paperPrimer H1-4 ForwardSigmaThis paperPrimer H1-4 ReverseSigmaThis paperAGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3C14 ForwardSigmaRuepp et al ⁵⁴ GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14-pre ForwardSigmaRuepp et al ⁵⁴ CCACCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre ForwardSigmaRuepp et al ⁵⁴ TCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre ReverseSigmaRuepp et al ⁵⁴ CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre ReverseSigmaThis paperCAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C14pre ReverseSigmaThis paperCAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGGCGCCGGAAGGTAGTTSigmaThis paper | | 0. | | | |
| Drimer H1-4 ForwardSigmaThis paperPrimer H1-4 ForwardSigmaThis paperPrimer H1-4 ReverseSigmaThis paperAGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4-pre ForwardSigmaThis paperCTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre ReverseSigmaThis paperATAGTGCAACAGCTCTTTACTGSigmaRuepp et al 54Primer H3C14 ForwardSigmaRuepp et al 54GCTGGTAAGCCTGTGTTTGGSigmaRuepp et al 54Primer H3C14 ReverseSigmaRuepp et al 54GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre ForwardSigmaRuepp et al 54TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre ReverseSigmaRuepp et al 54CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAAGCGGTACAGGTTATCAGAAGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGGCGCTGGAAAGGTAGGTTATCAGAAGTCSigmaThis paper | Primer H4C12 Reverse | Sigma | This paper | | |
| Primer H1-4 Polward TTCAACATGTCCGAGACTGCSigmaThis paperPrimer H1-4 Reverse AGGCGGCAACAGCTTTAGTASigmaThis paperPrimer H1-4 Pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3-4-pre Reverse ATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3C14 Forward GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al ⁵⁴ Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al ⁵⁴ Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C11 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C11 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | CAACCACCGAAACCGTAGAG | Sigmo | This paper | | |
| This Addition of the construction of the construct | | Sigilia | This paper | | |
| AGGCGGCAACAGCTTTAGTAOrginaHis paperPrimer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3-14 Forward GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al ⁵⁴ Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCCGCTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGCGCGCTATCAGAAGTCSigmaThis paper | Primer H1-4 Reverse | Sigma | This paper | | |
| Primer H1-4-pre Forward CTAAACCAAAGACCGCCAASigmaThis paperPrimer H1-4-pre Reverse ATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3C14 Forward GCTGGTAAGCCTGTGTTTGGSigmaRuepp et al ⁵⁴ Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Forward TTCCATCGTATCCAAAGGCTCTTSigmaRuepp et al ⁵⁴ Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paperPrimer H3C1 Reverse CAGGCGCGTGGAAGGTAGTTSigmaThis paper | AGGCGGCAACAGCTTTAGTA | Oigina | | | |
| CTAAACCAAAGACCGCCAAOrginalInterpretPrimer H1-4-pre ReverseSigmaThis paperATAGTGCAACAGCTCTTTTACTGSigmaRuepp et al 54Primer H3C14 ForwardSigmaRuepp et al 54GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al 54Primer H3C14 ReverseSigmaRuepp et al 54GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre ForwardSigmaRuepp et al 54TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre ReverseSigmaRuepp et al 54CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 ForwardSigmaThis paperAGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 ReverseSigmaThis paperCAGGCGCTGGAAAGGTAGTTSigmaThis paper | Primer H1-4-pre Forward | Sigma | This paper | | |
| Primer H1-4-pre Reverse ATAGTGCAACAGCTCTTTTACTGSigmaThis paperPrimer H3C14 Forward GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al 54Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | CTAAACCAAAGACCGCCAA | 0.9 | | | |
| ATAGTGCAACAGCTCTTTTACTGCPrimer H3C14 Forward GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al 54Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C14-pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | Primer H1-4-pre Reverse | Sigma | This paper | | |
| Primer H3C14 Forward GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al 54Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | ATAGTGCAACAGCTCTTTTACTG | 0 | | | |
| GCTGGTAAGCCTGTGTTTTGGSigmaRuepp et al 54Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | Primer H3C14 Forward | Sigma | Ruepp et al 54 | | |
| Primer H3C14 Reverse GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | GCTGGTAAGCCTGTGTTTTGG | - | | | |
| GCCGCCGGTCGACTTSigmaRuepp et al 54Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | Primer H3C14 Reverse | Sigma | Ruepp et al 54 | | |
| Primer H3C14-pre Forward TTCCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaRuepp et al 54Primer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | GCCGCCGGTCGACTT | | | | |
| LICCATCGTATCCAAAAGGCTCTTSigmaRuepp et al 54Primer H3C14pre Reverse CAAGCGGTACAGCTTCTTCCSigmaThis paperPrimer H3C1 Forward AGATCCGCCGTTATCAGAAGTCSigmaThis paperPrimer H3C1 Reverse CAGGCGCTGGAAAGGTAGTTSigmaThis paper | Primer H3C14-pre Forward | Sigma | Ruepp et al ⁵⁴ | | |
| Primer H3C14pre Reverse Sigma Ruepp et al ⁵⁴ CAAGCGGTACAGCTTCTTCC Sigma This paper Primer H3C1 Forward Sigma This paper AGATCCGCCGTTATCAGAAGTC Sigma This paper Primer H3C1 Reverse Sigma This paper CAGGCGCTGGAAAGGTAGTT Sigma This paper | | | | | |
| CAAGCGGTACAGCTTCTTCC Sigma Primer H3C1 Forward Sigma AGATCCGCCGTTATCAGAAGTC Sigma Primer H3C1 Reverse Sigma CAGGCGCTGGAAAGGTAGTT Sigma | Primer H3C14pre Reverse | Sigma | Ruepp et al ⁵⁴ | | |
| Primer H3C1 Forward Sigma This paper AGATCCGCCGTTATCAGAAGTC Sigma This paper Primer H3C1 Reverse Sigma This paper CAGGCGCTGGAAAGGTAGTT Sigma This paper | | Ciamaa | This paper | | |
| Primer H3C1 Reverse Sigma This paper | | Sigma | i nis paper | | |
| | | Sigma | This paper | | |
| | CAGGCGCTGGAAAGGTAGTT | Sigina | | | |

| Primer H3-3A Forward | Sigma | Cook et al ⁴⁹ |
|-------------------------------|------------------|-------------------------------|
| TAAAGCACCCAGGAAGCAAC | | |
| Primer H3-3A Reverse | Sigma | Cook et al 49 |
| AGGGAAGTTIGCGAATCAGA | 0. | 0 1 1 10 |
| Primer H3-3B Forward | Sigma | Cook et al 49 |
| | 0:200 | O a sha sh sh 40 |
| | Sigma | |
| Primor PDIA Equiprical | Sigmo | Simoonova et al 55 |
| | Sigilia | Simeonova et al |
| | Sigma | Simeonova et al ⁵⁵ |
| TTCATGCCTTCTTTCACTTTGC | Oigina | |
| Primer RPI PO Forward | Sigma | Simeonova et al 55 |
| CTTGTCTGTGGAGACGGATTACAC | olgina | |
| Primer RPLPO Reverse | Sigma | Simeonova et al 55 |
| TACGCCAAGAAGGCCTTGA | - 5 - | |
| Recombinant DNA | | |
| Plasmid: pEXPR-IBA105 | IBA | N/A |
| Plasmid: pEXPR-IBA105-ASF1a | IBA | Groth et al ²² |
| Plasmid: pEXPR-IBA105-ASF1b | IBA | Groth et al ²² |
| Software and algorithms | Ļ | ł |
| ImageJ (1.53) | ImageJ | http://imagei.nih.gov/ii |
| FlowJo (10.9.0) | BD Biosciences | http://www.flowio.com/ |
| Image Lab (6.1.0) | Bio-Rad | N/A |
| | Laboratories | |
| Python (3.9.5) | Python Software | https://www.python.org/dow |
| | Foundation | nloads/release/python-395/ |
| R (4.2.1) | R Project | https://www.r-project.org/ |
| Hisat2 (2.2.0) | Kim Lab @ UT | http://daehwankimlab.github |
| | Southwestern | .io/hisat2/ |
| Bedtools (2.30.0-13) | Quinlann Lab @ | https://github.com/arq5x/be |
| | U. of Utah | dtools2/releases |
| Bowtie2 (2.4.4) | Johns Hopkins | https://bowtie- |
| | University | bio.sourceforge.net/bowtie2 |
| | | <u>/index.shtml</u> |
| Samtools (1.12) | Sanger Institute | https://www.htslib.org/ |
| FeatureCounts (2.0.2) | University of | https://subread.sourceforge. |
| | Melbourne | net/featureCounts.html |
| Original code | N/A | nttps://doi.org/10.5281/zeno |
| | | 00.10412865 |
| | | 0.1//100005 |
| Dynabeads™ M-280 Streptavidin | Invitrogen | Cat#11206D |
| QIAfilter Plasmid Maxi kit | QIAGEN | Cat#12263 |

RESOURCE AVAILABILITY

Lead Contact

For further information and requests for resources and reagents contact the lead contact, Geneviève Almouzni (<u>genevieve.almouzni@curie.fr</u>).

Materials availability

All materials and reagents generated in this study are available upon request.

Data and Code Availability

- Sequencing data from RNA-seq in ArrayExpress (accession: <u>E-MTAB-12501</u>) Raw images for Western blots and microscope images at Mendeley Data (<u>https://doi.org/10.17632/2bbvdfrrct.1</u>).
- This paper report original code at Zenodo DOI: https://doi.org/10.5281/zenodo.10412865.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Cell line

We used the human cervical carcinoma cell line HeLa (ATCC, CC-L2). We cultured cells in DMEM complete medium (Dulbecco's Modified Eagle's Medium with D-Glucose, L-Glutamine and Pyruvate) supplemented with 10% fetal calf serum, 100 U/mL Penicillin and 100 mg/mL Streptomycin. The HeLa cell line tested negative for mycoplasma contamination.

METHOD DETAILS

Cell synchronization, HU treatment, EdU labeling, siRNA and plasmid transfections

We synchronized the cells in G1/S via double thymidine block: sequential exposure to 2 mM thymidine (16-18 hrs), 24 mM 2-Deoxycytidine (6 hrs) and 2 mM thymidine (18 hrs). For hydroxyurea (HU) treatment, we added HU at a final concentration of 0.1 mM to the cells 24 hrs before harvesting. For replication sites labeling, we added EdU at a final concentration of 10 mM to the cells 20 mins before harvesting. We visualized EdU using the Click-iT EdU Alexa Fluor 594 imaging kit (C10339, Invitrogen). We used the ImageJ software to quantify EdU fluorescence intensity in images acquired using a Zeiss Apotome widefield microscope (63x objective) (~300 nuclei for each condition). We transfected cells with siRNA at 100 nM concentration using Lipofectamine RNAiMAX (Invitrogen, 13778-150) as shown in Clément et al²¹ and with plasmids using Lipofectamine 2000 (Invitrogen, 11668-019). We listed sequences for siRNA in the Key resources table. We used Plasmids pEXPR-IBA105-ASF1a and -ASF1b expressing Onestrep-ASF1a and Onestrep-ASF1b, described in Groth et al ²².

FACS and immunofluorescence

After trypsinization, we counted cells using Vi-Cell XR Cell Viability Analyzer (Beckman coulter). We harvested around one million cells per condition using trypsin, fixed the cells with 70% cold ethanol and stained them with propidium iodide using FxCycle[™] PI/RNase solution (ThermoFisher Scientific, F10797), according to manufacturer's instructions. We acquired data using FACS Attune NxT machine (ThermoFisher Scientific) and assessed cell cycle profile with FlowJo software (10.9.0).

For immunofluorescence, after permeabilizing cells 5 mins with 0.2% Triton in PBS, we blocked with BSA (5% in PBS plus 0.1% Tween) before incubation with primary and secondary antibodies and DAPI staining. We mounted coverslips in Vectashield medium and used a Zeiss Apotome widefield microscope (63x objective).

4sU-labeled RNA-seq and total RNA-seq

For the 4sU-labeled RNA-seq, we cultured cells in 15 cm dish and added 10 ml of new medium containing 1 mM 4sU for 8 mins. ⁵¹ After 8 mins, we lysed the cells, and prepared total RNA directly from

the cell culture dishes using the RNeasy Mini Kit according to the manufacturer's instructions. The total RNA was DNase treated using the TURBO DNA-free kit (ThermoFisher Scientific, AM1907) or by RNase-free DNase (QIAGEN, 79254) using manufacturer's instructions. The quantity of isolated RNA was measured using the Nanodrop and we checked the quality by Tapestation. For 4sU-labeled RNA purification, we used 100-200 µg RNA for RNA biotinylation and carried out purification using Streptavidin-coupled Dynabeads (11206D, Invitrogen). We used 10 ng of total and 4sU-labeled RNAs for library preparation using SMARTer Stranded Total RNA-seq kit and performed paired-end sequencing by the next-generation sequencing platform at Institut Curie, providing pairs of 101 bp long reads.

RNA-seq analysis

We aligned reads on the human reference genome (GRCh38 assembly) based on EnsEMBL gene annotation (release 95) with hisat2 (version 2.1.0), run in paired-end mode with default parameters. We computed gene-level counts from primary alignments with MAPQ > 2 using featureCounts (Subread package version 1.6.3) in paired-end mode with the '-s 2' option for reverse-stranded libraries. We aligned reads on the sequences of the ERCC92 RNA spike in control from Life Technologies. Raw counts, human genome, and spike in control together, were normalized for differences in library size (counts per million), then these library-normalized counts for every human gene were normalized across samples by spike in control fraction. For normalization we used edgeR (version 3.28.0). We assessed the effect of ASF1 depletion in asynchronous cells by differential expression analyses with edgeR on genes with a quantifiable signal as evaluated by the function 'filterByExpr' of the same package with default parameters. In synchronized cells, in addition, we evaluated differential gene expression after release into S phase in control or in ASF1 depletion for each time point as indicated. Full details are provided in Table S1 (sheet 1), along with the counts normalized by spike in controls for both asynchronous (sheet 2) and synchronous cells (sheet 3). For hierarchical clustering analyses in synchronous cells, we included any DEG showing significant difference in expression in any comparison. Normalized counts were used for hierarchical clustering via Ward's variance minimization method and for comparing the expression of replicative histone genes from total or 4sU-labeled RNA-seq data generated in asynchronous cells. Functional enrichment analyses were carried out (Table S1, sheets 6 to 9). All RNA-seg analyses were carried out with custom Python scripts. Pandas (version 0.24.2), NumPy (version 1.16.2), SciPy (version 1.3.1) and fastcluster (version 1.1.26) libraries were used for data manipulation, statistical analysis, and hierarchical clustering. Matplotlib (version 2.2.4) and Seaborn (version 0.9.0) were used for plotting and visualization. R packages were imported into Python using the rpy2 module (version 2.8.4).

Analysis of unprocessed replicative histone transcripts from RNA-seq

We used RNA-seg data, total and 4sU-labeled, to determine the proportion of unprocessed replicative histone transcripts in siCtrl and siASF1 conditions. We located for every replicative histone gene the human SL sequence 'GGC(C/T)CTTTTCAG(A/G)GCC' from Marzluff et al.⁴ Then, we defined a region of 49 nucleotides from 20 nucleotides upstream of the SL sequence to 13 nucleotides downstream to reach the HDE, thus encompassing the cleavage site (scheme Figure S5B). We considered each RNA-seq fragment overlapping this region as indicative of an unprocessed transcript. For each replicative histone gene, we compared the number of reads mapping to the uncleaved 3' region of the gene, normalized by the window length, to the number of reads mapping on the ORF of the same gene, also normalized by the ORF length. Only fragments from concordant paired-end alignments, of length until 500 nucleotides and without gap (i.e., 'N' in the CIGAR string) in either of the two mate pairs were considered. Fragment counts were normalized across samples using DESeg2 median of ratios method. ⁵⁶ We computed the fraction of unprocessed transcripts by dividing the normalized fragment counts overlapping the uncleaved 3' region by the normalized count of fragments mapping on the ORF of the corresponding replicative histone gene. Then, we compared the relative amounts of unprocessed transcripts in siCtrl and siASF1 from the RNA-seg data in either asynchronous or synchronized cells. We considered replicative histone gene if the minimal raw count obtained over the corresponding ORF across the samples was equal or over 45 and if the gene had at least one unprocessed transcript in siCtrl condition.

Analysis of oligoadenylated transcripts

We used total and 4sU-labeled RNA-seq data to determine the fractions of replicative histone mRNAs oligoadenylated in siCtrl and siASF1 conditions. We first identified fragments or read pairs that carry oligoadenylation signature. As the sequencing was reversed stranded, we looked in name-sorted alignments for pairs with the second read mapping in sense on replicative histone genes and filtered these pairs by first read carrying at least 22 'T's from the 5' end, which prevent selecting first reads matching in reverse any 'A' stretches present downstream of a few of replicative histone genes. Note that the first read may not map on genome because of the adenylation signature. The low amount of read pairs detected led us to sum per sample the counts over all the replicative histone genes. In addition, we normalized these counts using the spike in controls. For highly expressed genes, we calculated the average ranking of all genes throughout the samples. We could thus define the second decile of most expressed genes across the RNA-seq samples of synchronized cells.

Reverse transcription- quantitative PCR (RT-qPCR)

To obtain cDNA, we performed reverse transcription PCR using 1 µg of RNA for each sample using the SuperScriptTM III First Strand Synthesis SuperMix (Invitrogen, 11752-050) according to manufacturer's instructions. We performed quantitative PCR using PowerSYBR Green PCR Master Mix (ABI, 4367659) with three technical replicates in 384-well plates using the QuantStudio 5 Real-Time PCR machine. We calculated relative expression by $\Delta\Delta$ ct method, where we substracted the Ct values for PPIA endogenous control from each gene of interest (Δ ct) and then for normalization, we subtracted the Δ ct of the control (siCtrl) condition for each gene of interest ($\Delta\Delta$ ct). We calculated relative expression as the fold change and plotted using 2^($\Delta\Delta$ ct). We listed primers in the Key resources. For a given condition, we estimated significance of the fold changes with a Student test ("t.test" function in R). The fold changes were log transformed prior to a comparison with the same distribution of the values centred on 0; or with the distribution of another condition in case of comparing two conditions. The tests are "two.sided" or oriented according the experiment.

Protein extraction and Western blotting

We prepared cytosolic and nuclear extracts from HeLa cells according to Martini et al ⁵⁷ but using 300 mM NaCl for nuclear extracts. Briefly, after lysing cells in hypotonic buffer using Dounce homogenizer and centrifugation, we collected the supernatant (cytosolic extract) and treated the pellet with lysis buffer containing 300 mM NaCl. After centrifugation, the supernatant (nuclear extract) was collected, and the pellet treated with benzonase and sonicated. After centrifugation the supernatant containing the chromatin fraction was collected. We quantified extracts using Protein Assay Dye Reagent Concentrate (Bio-Rad, 5000006). For whole cell extracts, cells were resuspended in NuPAGE 1X LDS sample buffer supplemented with Sample reducing agent (invitrogen), treated with benzonase and sonicated. The samples were loaded on Bis-Tris 4-12% gel (NuPage, Invitrogen)) with PageRuler protein ladder. We run gels at 120 V for ~1.5 hrs and then transferred them onto a 0.2 µm nitrocellulose membrane using BioRad Turbo Transblot, Membranes were stained using Pierce reversible protein stain to check the transfer efficiency, blocked in 5% milk prepared in PBST for one hour at room temperature, then incubated in primary antibodies (Key resources table) diluted in 3% BSA-PBST at 4°C overnight on a rocker. Of note, for H3.3 and H3.1/2 Western blots, we incubated the same membrane first with the mouse anti-H3.1/2 antibody, then with the rabbit anti-H3.3 antibody. Membranes were then washed with PBST and incubated in secondary antibodies conjugated with horseradish peroxidase (HRP) with 5% milk PBST for one hour at room temperature. Secondary antibodies were prepared in dilutions of either 1:20,000 (rabbit) or 1:10,000 (mouse). Membranes were then washed with PBST, then exposed with SuperSignal West Pico PLUS chemiluminescent reagent. Membranes were imaged using ChemiDoc Touch system and processed with ImageLab software (Bio-Rad). We performed quantitative analysis of Western blots using tubulin normalization and estimated fold changes from at least three different Western blots and two different experiments.

Antibodies

For Western blots we used the following antibodies: ASF1a (1:2000, 2990, Cell Signaling), ASF1b (1:500, Agrobio²⁴), H3.1/2 (1:500 for soluble extract and 1:5000 for chromatin fraction, 61629, Active Motif), H3.3 (1:500 for soluble extract and 1:5000 for chromatin fraction, 09-838, Millipore), H4 (1:500, ab31830, Abcam), H2B (1:1000, ab1790, Abcam), p60 CAF-1 (1:1000, Agrobio²⁴), SLBP (1:500, ab181972,

Abcam), HIRA (1:100, WC119.2H11, Active Motif), γ-tubulin (1:2000, T5326, Sigma) and vinculin (1:1000, V9131, Sigma). For Immunofluorescence, we used the following antibodies: FLASH (1:300, HPA053573, Sigma) and NPAT (1:100, PA5-66839, Invitrogen).

QUANTIFICATION AND STATISTICAL ANALYSIS

Results of statistical tests are displayed by at least a symbol code on the corresponding panel (*: <0.05, **: <0.01, ***:<0.001, 'ns': non-significant). The p-value may be indicated below, or in the Figure legend to illustrate arguments. For genome wide comparisons, the p-values are presented in the Table S1. The type of statistical test depends on the comparison performed which is detailed in the following subsections. All the statistical tests were performed in R, with base statistical functions ('t.test' for mean comparison, 'glm' for applying a GLM) or with R packages indicated for the corresponding cases.

RNA-seq analysis

Differential expression analyses were performed with edgeR (version 3.28.0) on genes having a quantifiable signal as evaluated by the function 'filterByExpr' of the same package with default parameters. We assessed the effect of ASF1 depletion in asynchronous cells by fitting a quasi-likelihood negative binomial generalized log-linear model (GLM) comparing siASF1 to control.

To evaluate the effect of ASF1 depletion in synchronized cells before (0 hr) and after release into S phase (2 hrs), we similarly fitted a GLM including both additive and synergistic terms to model the stand-alone effect of S phase progression (changes in expression at 2 and 5 hrs relative to 0 hr) and ASF1 depletion (siASF1 relative to control across all time points), as well as at the specific effect of ASF1 depletion at different time points after release into S phase (siASF1 relative to control at 2 and 5 hrs). Full details about the variable encoding and GLM formulation are provided in Table S1 (sheet 1). For each effect, we applied a quasi-likelihood F-test on the respective GLM coefficient to assess its significance, followed by multiple testing correction via the Benjamini-Hochberg method (Table S1, sheet 4 for asynchronous cells and sheet 5 for synchronous cells). A false discovery rate (FDR) cut-off of 0.05 was used to identify differentially expressed genes (DEGs).

Functional enrichment analyses were carried out using the WebGestaltR package (version 0.4.2). For asynchronous cells, we evaluated the enrichment in Hallmark signatures from MSigDB by over-representation analysis (ORA) for the top 100 upregulated and top 100 downregulated genes, ranked by FDR (Table S1, sheets 6 and 7). For synchronous cells, we checked enrichment in biological processes associated to specific DEG clusters using Gene Ontology (GO) annotations (Table S1, sheets 8 and 9).

Analysis of unprocessed replicative histone transcripts from RNA-seq

Differential fraction of uncleaved transcripts was evaluated with a GLM (with gaussian family of link function) which considers the 'replicate identity', the 'condition' and the 'synergy' between the two. The p-value is the significance of the 'condition' term testing if this term has a coefficient greater than 0.

Metagene analysis of RNA-seq signal of replicative histones and downstream of their SL

We computed the coverage along the genome directly from the mapped reads, using "bedtools genomecov" command with options "-bga" and "-split". We recovered the coverage signal along the region from the TSS to 500 bases downstream of the SL of the replicative histone genes and normalized it based on sequencing depth and spike-in controls followed by a reduction to the geometric mean of expression of the set of genes. We then summarized in 20 bins by averaging the signal along the region from the TSS to the SL. Downstream of the SL, the signal is summarized in bins of 10 bases. We then compute the fold change from control to ASF1 depleted condition, in respect of the replicate, in every bin.

Reverse transcription-quantitative PCR (RT-qPCR)

For a given condition, significance of the fold changes was evaluated with a Student test ("t.test" function in R). The fold changes were log transformed prior to a comparison with the same distribution of the values centred on 0; or with the distribution of another condition in case of comparing two conditions. The tests are "two.sided" or oriented according the experiment.

ADDITIONAL RESOURCES

None.

Table S1. Analysis of RNA-seq data, related to Figures 2, 4, S3 and S5

Sheet 1: provides the summary of the next excel sheets; Sheet 2 TMM (Trimmed Mean of the M-values)-normalized counts from total RNA-seq in asynchronous cells, related to Figures 3A, 3B, 3C and S3A; Sheet 3: TMM-normalized counts from total RNA-seq in cells synchronized at G1/S, related to Figures 2C, 2D, 2E, S3D and S3E; Sheet 4: Differential gene expression analysis comparing siASF1 with siCtrl samples using data from total RNA-seq in asynchronous cells, related to Figures 2A, 3D and S3B; Sheet 5: Differential gene expression analysis comparing siASF1 with siCtrl samples using data from total RNA-seq in cells synchronized at G1/S, related to Figure 2C; Sheet 6: Over-Representation Analysis (ORA) in hallmark signatures for the top 100 upregulated genes from total RNA-seq in asynchronous cells, related to Figure S3B; Sheet 7: Id to Sheet 6 but for the top 100 downregulated genes, related to Figure S3B; Sheet 8: Hierarchical clustering of differentially expressed genes (DEGs) in synchronized cells, related to Figures 2C, 2D, 2E, 3B, 3C, S3C and S3D; Sheet 9: For genes identified by hierarchical clustering (DEG clusters) in synchronized cells, their Over-Representation Analysis (ORA) in defined biological processes (Gene ontology classification), related to Figure S3C; Sheet 10: Signals (read counts) corresponding to 4sU-labeled RNA-seq spanning over the region downstream of the Stem Loop compared to the signals spanning over the ORF of the replicative histone gene expressed as a ratio, related to Figures 4A and S5A.

REFERENCES

- 1. Luger, K. (1997). Crystal structure of the nucleosome core particle at 2.8 A° resolution. 389.
- 2. Zhou, K., Gaullier, G., and Luger, K. (2019). Nucleosome structure and dynamics are coming of age. Nat Struct Mol Biol *26*, 3–13. 10.1038/s41594-018-0166-x.
- 3. Armstrong, C., and Spencer, S.L. (2021). Replication-dependent histone biosynthesis is coupled to cell-cycle commitment. Proc. Natl. Acad. Sci. U.S.A. *118*, e2100178118. 10.1073/pnas.2100178118.
- 4. Marzluff, W.F., Wagner, E.J., and Duronio, R.J. (2008). Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet *9*, 843–854. 10.1038/nrg2438.
- 5. Mendiratta, S., Gatto, A., and Almouzni, G. (2019). Histone supply: Multitiered regulation ensures chromatin dynamics throughout the cell cycle. Journal of Cell Biology 218, 39–54. 10.1083/jcb.201807179.
- 6. Marzluff, W.F., and Koreski, K.P. (2017). Birth and Death of Histone mRNAs. Trends in Genetics 33, 745–759. 10.1016/j.tig.2017.07.014.
- Hur, W., Kemp, J.P., Tarzia, M., Deneke, V.E., Marzluff, W.F., Duronio, R.J., and Di Talia, S. (2020). CDK-Regulated Phase Separation Seeded by Histone Genes Ensures Precise Growth and Function of Histone Locus Bodies. Developmental Cell 54, 379-394.e6. 10.1016/j.devcel.2020.06.003.
- 8. Nizami, Z., Deryusheva, S., and Gall, J.G. (2010). The Cajal Body and Histone Locus Body. Cold Spring Harbor Perspectives in Biology 2, a000653–a000653. 10.1101/cshperspect.a000653.
- 9. Harris, M.E., Böhni, R., Schneiderman, M.H., Ramamurthy, L., Schümperli, D., and Marzluff, W.F. (1991). Regulation of histone mRNA in the unperturbed cell cycle: evidence suggesting control at two posttranscriptional steps. VOL ., 9.
- Gurard-Levin, Z.A., Quivy, J.-P., and Almouzni, G. (2014). Histone Chaperones: Assisting Histone Traffic and Nucleosome Dynamics. Annu. Rev. Biochem. 83, 487–517. 10.1146/annurev-biochem-060713-035536.
- 11. Hammond, C.M., Strømme, C.B., Huang, H., Patel, D.J., and Groth, A. (2017). Histone chaperone networks shaping chromatin function. Nat Rev Mol Cell Biol *18*, 141–158. 10.1038/nrm.2016.159.
- Moggs, J.G., Grandi, P., Quivy, J.-P., Jónsson, Z.O., Hübscher, U., Becker, P.B., and Almouzni, G. (2000). A CAF-1–PCNA-Mediated Chromatin Assembly Pathway Triggered by Sensing DNA Damage. Mol Cell Biol 20, 1206–1218. 10.1128/MCB.20.4.1206-1218.2000.
- Smith, S., and Stillman, B. (1989). Purification and characterization of CAF-I, a human cell factor required for chromatin assembly during DNA replication in vitro. Cell 58, 15–25. 10.1016/0092-8674(89)90398-X.
- Abascal, F., Corpet, A., Gurard-Levin, Z.A., Juan, D., Ochsenbein, F., Rico, D., Valencia, A., and Almouzni, G. (2013). Subfunctionalization via Adaptive Evolution Influenced by Genomic Context: The Case of Histone Chaperones ASF1a and ASF1b. Molecular Biology and Evolution 30, 1853– 1866. 10.1093/molbev/mst086.

- 15. Le, S., Davis, C., Konopka, J.B., and Sternglanz, R. (1997). Two New S-Phase-Specific Genes fromSaccharomyces cerevisiae. Yeast *13*, 1029–1042. 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1.
- Tagami, H., Ray-Gallet, D., Almouzni, G., and Nakatani, Y. (2004). Histone H3.1 and H3.3 Complexes Mediate Nucleosome Assembly Pathways Dependent or Independent of DNA Synthesis. Cell 116, 51–61. 10.1016/S0092-8674(03)01064-X.
- 17. Mello, J.A., Silljé, H.H.W., Roche, D.M.J., Kirschner, D.B., Nigg, E.A., and Almouzni, G. (2002). Human Asf1 and CAF- 1 interact and synergize in a repair- coupled nucleosome assembly pathway. EMBO Rep *3*, 329–334. 10.1093/embo-reports/kvf068.
- Tyler, J.K., Adams, C.R., Chen, S.-R., Kobayashi, R., Kamakaka, R.T., and Kadonaga, J.T. (1999). The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature 402, 555–560. 10.1038/990147.
- Ahmad, K., and Henikoff, S. (2002). The Histone Variant H3.3 Marks Active Chromatin by Replication-Independent Nucleosome Assembly. Molecular Cell 9, 1191–1200. 10.1016/S1097-2765(02)00542-7.
- Tang, Y., Poustovoitov, M.V., Zhao, K., Garfinkel, M., Canutescu, A., Dunbrack, R., Adams, P.D., and Marmorstein, R. (2006). Structure of a human ASF1a–HIRA complex and insights into specificity of histone chaperone complex assembly. Nat Struct Mol Biol 13, 921–929. 10.1038/nsmb1147.
- Clément, C., Orsi, G.A., Gatto, A., Boyarchuk, E., Forest, A., Hajj, B., Miné-Hattab, J., Garnier, M., Gurard-Levin, Z.A., Quivy, J.-P., et al. (2018). High-resolution visualization of H3 variants during replication reveals their controlled recycling. Nat Commun 9, 3181. 10.1038/s41467-018-05697-1.
- 22. Groth, A., Corpet, A., Cook, A.J.L., Roche, D., Bartek, J., Lukas, J., and Almouzni, G. (2007). Regulation of Replication Fork Progression Through Histone Supply and Demand. Science *318*, 1928–1931. 10.1126/science.1148992.
- Torné, J., Ray-Gallet, D., Boyarchuk, E., Garnier, M., Le Baccon, P., Coulon, A., Orsi, G.A., and Almouzni, G. (2020). Two HIRA-dependent pathways mediate H3.3 de novo deposition and recycling during transcription. Nat Struct Mol Biol 27, 1057–1068. 10.1038/s41594-020-0492-7.
- Groth, A., Ray-Gallet, D., Quivy, J.-P., Lukas, J., Bartek, J., and Almouzni, G. (2005). Human Asf1 Regulates the Flow of S Phase Histones during Replicational Stress. Molecular Cell 17, 301–311. 10.1016/j.molcel.2004.12.018.
- Sutton, A., Bucaria, J., Osley, M.A., and Sternglanz, R. (2001). Yeast ASF1 Protein Is Required for Cell Cycle Regulation of Histone Gene Transcription. Genetics 158, 587–596. 10.1093/genetics/158.2.587.
- Barcaroli, D., Bongiorno-Borbone, L., Terrinoni, A., Hofmann, T.G., Rossi, M., Knight, R.A., Matera, A.G., Melino, G., and De Laurenzi, V. (2006). FLASH is required for histone transcription and S-phase progression. Proc. Natl. Acad. Sci. U.S.A. 103, 14808–14812. 10.1073/pnas.0604227103.

- Yang, X., Burch, B.D., Yan, Y., Marzluff, W.F., and Dominski, Z. (2009). FLASH, a Proapoptotic Protein Involved in Activation of Caspase-8, Is Essential for 3' End Processing of Histone PremRNAs. Molecular Cell 36, 267–278. 10.1016/j.molcel.2009.08.016.
- 28. Koç, A., Wheeler, L.J., Mathews, C.K., and Merrill, G.F. (2004). Hydroxyurea Arrests DNA Replication by a Mechanism That Preserves Basal dNTP Pools. Journal of Biological Chemistry 279, 223–230. 10.1074/jbc.M303952200.
- 29. Gao, Y., Gan, H., Lou, Z., and Zhang, Z. (2018). Asf1a resolves bivalent chromatin domains for the induction of lineage-specific genes during mouse embryonic stem cell differentiation. Proc. Natl. Acad. Sci. U.S.A. *115*. 10.1073/pnas.1801909115.
- Armstrong, C., Passanisi, V.J., Ashraf, H.M., and Spencer, S.L. (2023). Cyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis. Cell Reports 42, 112768. 10.1016/j.celrep.2023.112768.
- 31. Sullivan, K.D., Mullen, T.E., Marzluff, W.F., and Wagner, E.J. (2009). Knockdown of SLBP results in nuclear retention of histone mRNA. RNA *15*, 459–472. 10.1261/rna.1205409.
- Sànchez, R., and Marzluff, W.F. (2002). The Stem-Loop Binding Protein Is Required for Efficient Translation of Histone mRNA In Vivo and In Vitro. Molecular and Cellular Biology 22, 7093–7104. 10.1128/MCB.22.20.7093-7104.2002.
- Nelson, D.M., Ye, X., Hall, C., Santos, H., Ma, T., Kao, G.D., Yen, T.J., Harper, J.W., and Adams, P.D. (2002). Coupling of DNA Synthesis and Histone Synthesis in S Phase Independent of Cyclin/cdk2 Activity. Mol Cell Biol 22, 7459–7472. 10.1128/MCB.22.21.7459-7472.2002.
- 34. Morales Torres, C., Wu, M.Y., Hobor, S., Wainwright, E.N., Martin, M.J., Patel, H., Grey, W., Grönroos, E., Howell, S., Carvalho, J., et al. (2020). Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. Nat Commun *11*, 1792. 10.1038/s41467-020-15615-z.
- 35. Torres, C.M., Biran, A., Burney, M.J., Patel, H., Henser-Brownhill, T., Cohen, A.-H.S., Li, Y., Ben-Hamo, R., Nye, E., Spencer-Dene, B., et al. (2016). The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science *353*, aaf1644. 10.1126/science.aaf1644.
- 36. Ma, T., Van Tine, B.A., Wei, Y., Garrett, M.D., Nelson, D., Adams, P.D., Wang, J., Qin, J., Chow, L.T., and Harper, J.W. (2000). Cell cycle–regulated phosphorylation of p220 ^{NPAT} by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 14, 2298–2313. 10.1101/gad.829500.
- Zhao, J., Kennedy, B.K., Lawrence, B.D., Barbie, D.A., Matera, A.G., Fletcher, J.A., and Harlow, E. (2000). NPAT links cyclin E–Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev. 14, 2283–2297. 10.1101/gad.827700.
- Narita, T., Yung, T.M.C., Yamamoto, J., Tsuboi, Y., Tanabe, H., Tanaka, K., Yamaguchi, Y., and Handa, H. (2007). NELF Interacts with CBC and Participates in 3' End Processing of Replication-Dependent Histone mRNAs. Molecular Cell 26, 349–365. 10.1016/j.molcel.2007.04.011.
- Romeo, V., Griesbach, E., and Schümperli, D. (2014). CstF64: Cell Cycle Regulation and Functional Role in 3' End Processing of Replication-Dependent Histone mRNAs. Mol Cell Biol 34, 4272–4284. 10.1128/MCB.00791-14.

- 40. Saldi, T., Fong, N., and Bentley, D.L. (2018). Transcription elongation rate affects nascent histone pre-mRNA folding and 3' end processing. Genes Dev. *32*, 297–308. 10.1101/gad.310896.117.
- Sullivan, E., Santiago, C., Parker, E.D., Dominski, Z., Yang, X., Lanzotti, D.J., Ingledue, T.C., Marzluff, W.F., and Duronio, R.J. (2001). *Drosophila* stem loop binding protein coordinates accumulation of mature histone mRNA with cell cycle progression. Genes Dev. 15, 173–187. 10.1101/gad.862801.
- 42. Ogami, K., Chen, Y., and Manley, J. (2018). RNA Surveillance by the Nuclear RNA Exosome: Mechanisms and Significance. ncRNA 4, 8. 10.3390/ncrna4010008.
- 43. Ogami, K., and Suzuki, H.I. (2021). Nuclear RNA Exosome and Pervasive Transcription: Dual Sculptors of Genome Function. IJMS 22, 13401. 10.3390/ijms222413401.
- Wagner, E.J., Burch, B.D., Godfrey, A.C., Salzler, H.R., Duronio, R.J., and Marzluff, W.F. (2007). A Genome-wide RNA Interference Screen Reveals that Variant Histones Are Necessary for Replication-Dependent Histone Pre-mRNA Processing. Molecular Cell 28, 692–699. 10.1016/j.molcel.2007.10.009.
- Mejlvang, J., Feng, Y., Alabert, C., Neelsen, K.J., Jasencakova, Z., Zhao, X., Lees, M., Sandelin, A., Pasero, P., Lopes, M., et al. (2014). New histone supply regulates replication fork speed and PCNA unloading. Journal of Cell Biology 204, 29–43. 10.1083/jcb.201305017.
- 46. Hoek, M., and Stillman, B. (2003). Chromatin assembly factor 1 is essential and couples chromatin assembly to DNA replication *in vivo*. Proc. Natl. Acad. Sci. U.S.A. *100*, 12183–12188. 10.1073/pnas.1635158100.
- 47. Sherwood, P.W. (1993). Characterization of HIRJ and HIR2, Two Genes Required for Regulation of Histone Gene Transcription in Saccharomyces cerevisiae. MOL. CELL. BIOL. 13, 11.
- Spector, M.S., Raff, A., DeSilva, H., Lee, K., and Osley, M.A. (1997). Hir1p and Hir2p function as transcriptional corepressors to regulate histone gene transcription in the Saccharomyces cerevisiae cell cycle. Mol Cell Biol 17, 545–552. 10.1128/MCB.17.2.545.
- 49. Cook, A.J.L., Gurard-Levin, Z.A., Vassias, I., and Almouzni, G. (2011). A Specific Function for the Histone Chaperone NASP to Fine-Tune a Reservoir of Soluble H3-H4 in the Histone Supply Chain. Molecular Cell *44*, 918–927. 10.1016/j.molcel.2011.11.021.
- 50. Ray-Gallet, D., and Almouzni, G. (2022). H3–H4 histone chaperones and cancer. Current Opinion in Genetics & Development 73, 101900. 10.1016/j.gde.2022.101900.
- 51. Fuchs, G., Voichek, Y., Rabani, M., Benjamin, S., Gilad, S., Amit, I., and Oren, M. (2015). Simultaneous measurement of genome-wide transcription elongation speeds and rates of RNA polymerase II transition into active elongation with 4sUDRB-seq. Nat Protoc 10, 605–618. 10.1038/nprot.2015.035.
- 52. Polo, S.E., Roche, D., and Almouzni, G. (2006). New Histone Incorporation Marks Sites of UV Repair in Human Cells. Cell 127, 481–493. 10.1016/j.cell.2006.08.049.
- 53. Ray-Gallet, D., Woolfe, A., Vassias, I., Pellentz, C., Lacoste, N., Puri, A., Schultz, D.C., Pchelintsev, N.A., Adams, P.D., Jansen, L.E.T., et al. (2011). Dynamics of Histone H3 Deposition In Vivo Reveal

a Nucleosome Gap-Filling Mechanism for H3.3 to Maintain Chromatin Integrity. Molecular Cell 44, 928–941. 10.1016/j.molcel.2011.12.006.

- 54. Ruepp, M.-D., Vivarelli, S., Pillai, R.S., Kleinschmidt, N., Azzouz, T.N., Barabino, S.M.L., and Schümperli, D. (2010). The 68 kDa subunit of mammalian cleavage factor I interacts with the U7 small nuclear ribonucleoprotein and participates in 3'-end processing of animal histone mRNAs. Nucleic Acids Research *38*, 7637–7650. 10.1093/nar/gkq613.
- 55. Simeonova, I., Lejour, V., Bardot, B., Bouarich-Bourimi, R., Morin, A., Fang, M., Charbonnier, L., and Toledo, F. (2012). Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target Genes. PLoS Genet 8, e1002731. 10.1371/journal.pgen.1002731.
- 56. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol *15*, 550. 10.1186/s13059-014-0550-8.
- 57. Martini, E., Roche, D.M.J., Marheineke, K., Verreault, A., and Almouzni, G. (1998). Recruitment of Phosphorylated Chromatin Assembly Factor 1 to Chromatin after UV Irradiation of Human Cells. Journal of Cell Biology *143*, 563–575. 10.1083/jcb.143.3.563.





FIGURE 3





FIGURE 4

Cleavage

site

SL

A Metagene analysis of Group 2 genes

B RT-qPCR - pre-mRNA/unprocessed transcript





C Synthesis and usage of replicative histones in S phase



SUPPLEMENTAL INFORMATION

Regulation of replicative histone RNA metabolism by the histone chaperone ASF1

Shweta Mendiratta, Dominique Ray-Gallet, Sébastien Lemaire, Alberto Gatto, Audrey Forest, Maciej A. Kerlin and Geneviève Almouzni

SUPPLEMENTAL FIGURES



Figure S1. ASF1 depletion reduces replicative histones at the levels of both soluble protein and total RNA, Related to Figure 1

(A) (Left) Western blot analysis of whole HeLa cell extract from siCtrl-, siASF1-, siFLASH-, siSLBP-, siASF1a-, siASF1b-, sip60 (CAF-1)- or siHIRA-treated cells showing the efficiency of depletions. We used extracts corresponding to the same number of cells (1x and 2x) and γ -tubulin as loading control. Following both FLASH and SLBP depletions, ASF1a and ASF1b signals decreased while slower migrating bands, likely phosphorylated forms ^{S1,S2}, appeared in line with S phase cell accumulation. However, HU-treated cells, also accumulate in S phase, and do not show this, thus we consider that other effects deserve investigation. (Right) Immunofluorescence analysis of FLASH in siCtrl- or siFLASH-treated HeLa cells. The nuclei are visualized by DAPI staining. The insets represent enlarged images of selected cells. Scale bar 10 μ m. (B) EdU labeling of replicating cells in Ctrl-, ASF1-, sip60- or FLASH-depleted cells and in control (-HU) and HU-treated (+HU) cells. Scale bar 10 µm. (C) Quantification of EdU fluorescence intensity in arbitrary units (a.u.) from two siRNA- and two HU-treatment experiments (exp1 and exp2). (D) (Left) Western blot analysis of whole cell extracts from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl, siASF1a (#2 or #3), siASF1b (#2 or #3) or ASF1a+b (#2 or #3)). We used extracts corresponding to the same number of cells (1x and 2x). We examined ASF1a and ASF1b and used vinculin as loading control. (Right) Western blot analysis of cytosolic extract from HeLa cells harvested 48 hrs after siRNA transfection with siCtrl or ASF1a+b (#1, #2 or #3). We examined the replicative histones H3.1/H3.2 and the non-replicative histone H3.3. We used 10 and 20 μ g of extracts and vinculin as loading control. (E) Western blot analysis of nuclear extract from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl, siASF1, siCAF-1-p60 or siFLASH) or 24 hrs after HU treatment (+HU) or control (-HU). We examined ASF1a and b, p60, the replicative histones H3.1/H3.2 and the non-replicative histone H3.3. We used 10 and 20 μ g of extracts and γ -tubulin as loading control. (F) Western blot analysis of cytosolic extract from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl or siASF1). We examined the replicative histones H3.1/H3.2, H4 and H2B. We used 10 and 20 μ g of extracts and γ -tubulin as loading control.



Figure S2, Related to Figure 1

Figure S2. ASF1 depletion rescue and impact of siSLBP, siASF1a, siASF1b and siHIRA transfections on replicative histones, Related to Figure 1

(A) Rescue experiment. HeLa cells were transfected with siRNAs (siCtrl or siASF1), then, 24 hrs later with expression vectors, either with the empty vector pEXPR-IBA105 (Strep) or with those expressing Onestrep-ASF1a and Onestrep-ASF1b (Strep-ASF1a+b). The cells were harvested 48 hrs after siRNA transfection and either proteins or total RNA were prepared. (Left) Western blot analysis of cytosolic extract. Two amounts 1x and 2x were loaded. We examined ASF1a and ASF1b, replicative histones H3.1/H3.2 and H4 and the non-replicative H3.3 and used γ -tubulin as loading control. (Right) RT-qPCR analysis. Individual histone genes are the replicative H2AC20 (H2A type 2-C) and H4C12 (H4) and the non-replicative H3-3B (H3.3). The fold change in transcript levels as compared to siCtrl+Strep corresponds to the mean of two independent biological replicate experiments. (B) FACS analysis of the cells 48 hrs after siRNAs transfection (siSLBP, siASF1a, siASF1b or siHIRA). We stained cells with PI and analyzed DNA content by flow cytometry. Percentages of cells in G1, S and G2/M are indicated. (C) EdU labeling of replicating cells as described in panel (B) for SLBP-, ASF1a-, ASF1-b and HIRA-depleted cells. Scale bar 10 µm. (D) EdU fluorescence quantification as described in panel (C) for SLBP-, ASF1a-, ASF1-b and HIRA-depleted cells. (E) Western blots of cytosolic and nuclear extracts from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl, siASF1, siASF1a, siASF1b, siSLBP or siHIRA). We used 10 and 20 μ g of extracts and γ -tubulin as loading control. (F) RT-qPCR analysis of histone RNA levels. Total RNA was isolated from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl, siSLBP, siASF1a, siASF1b or siHIRA). We show individual histone genes: the replicative genes (in black) H2AC20 and H3C14 and the non-replicative genes (in white) H3-3A and H3-3B. Fold changes in transcript levels for siSLBP, siASF1a, siASF1b and siHIRA transfected cells relative to siCtrl are shown.

Figure S3, Related to Figure 2



С Total RNA-seq - Synchronized cells

Group 1

2.7 o spinal cord development

2.1 o double-strand break repair

Group 4

2.6 • positive regulation of ion transport

2.6 • regulation of ion transmembrane...

2.3 • divalent inorganic cation transport

Histone genes

3.1 • cell-cell adhesion via...

2.5 · leukocyte migration

D

1.9 o cellular carbohydrate metabolic process1.8 o pattern specification process

2.3 • DNA replication

Replicative histone genes Group 2

- 69.0 chromatin assembly or disassembly45.7 DNA conformation change
 - 44.8 protein-DNA complex subunit organization
 - 23.0 gene silencing 16.7 regulation of gene expression,...

Group 5

- 1.8 sensory perception of mechanical... 1.6 extracellular structure organization
- 1.5 regulation of ion transmembrane ...
- 1.5 regulation of neuron projection...1.5 axon development

Group 3

- 2.3 mitochondrial respiratory chain ...
- 2.0 protein localization to endoplasmic ... 1.7 • nucleoside triphosphate metabolic ...
- 1.6 RNA splicing 1.6 mRNA processing

Group 6

- 1.9 rRNA metabolic process
- 1.7 ncRNA processing 1.7 • I-kappaB kinase/NF-kappaB signaling
- 1.6 ribonucleoprotein complex biogenesis
- 1.5 response to oxygen levels

• FDR < 5%

Replicative histone genes

Е





6

Figure S3. Impact of ASF1 depletion on transcriptome - RNA-seq data from asynchronous and synchronized HeLa cells in siCtrl and siASF1 conditions, Related to Figure 2

(A) Heat map showing hierarchical clustering of samples (rows) and differentially expressed genes (columns) between siCtrl and siASF1 conditions in asynchronous cells, including all genes showing significant differences at FDR < 0.05. The color gradient is proportional to the expression of each gene in each sample, relative to their average across all samples (log2 normalized counts, meancentered): from blue (lower than average) to red (higher than average). The experiment was performed in duplicate, replicate 1 (R1) and replicate 2 (R2). (B) (Left) MA plot showing log2 fold change between siASF1 and siCtrl versus baseline expression levels across all genes. Differentially expressed genes at FDR < 0.05 are highlighted in blue (downregulated) or red (upregulated). (Right) Hallmark signatures associated with the top 100 upregulated (top panel) or downregulated genes (bottom panel), as identified by over-representation analysis (ORA) with WebGestaltR v0.4.2. Signatures showing significant enrichment at FDR < 0.05 are highlighted in red (for upregulated genes) and blue (for downregulated genes). (C) Six groups of genes identified by hierarchical clustering from differential gene expression between siASF1 and siCtrl in synchronized HeLa cells (see Figures 2C and 2E). For all groups of genes, the top 5 Gene Ontology (GO) annotations are shown (over-representation analysis with WebGestaltR, v0.4.2). GO terms showing significant enrichment at FDR < 0.05 are highlighted in black. Group 2 corresponds only to replicative histone genes. (D) Heat map showing hierarchical clustering of all replicative histone genes and non-replicative histone genes in siCtrl and siASF1 conditions. Color gradient shows expression relative to average as in Figure 2C (log2 normalized counts, mean-centred): from blue (lower than average) to red (higher than average). (E) The box plots show the distribution of relative expression levels of all replicative histone genes in siCtrl (in blue) and siASF1 (in red) conditions at 0 (G1/S), 2 and 5 hrs (S phase) after release from the G1/S block (log2 normalized counts, mean-centered across all samples and averaged by experimental condition). See also supplementary Table.



Immunofluorescence analysis of FLASH and NPAT in siRNA- and HU-treated cells

Figure S4. Immunofluorescence analysis of FLASH and NPAT after siRNA and HU treatments, Related to Figure 3

Immunofluorescence analysis of FLASH (top) and NPAT (bottom) in HeLa cells treated with siRNA (siCtrl, siASF1, sip60 CAF1 and siFLASH) or with HU (+HU) and control without drug (-HU). The nuclei are visualized by DAPI staining. The insets represent enlarged images of selected cells. Scale bar 10 μ m.



A Integrative Genomic Viewer (IGV) snapshots - 4sU-RNA-seq

B Unprocessed replicative histone transcripts





R1 R2 R1 R2



RT-qPCR - pre-mRNA



Figure S5. ASF1 depletion affects the 3'-end processing of replicative histone transcripts, Related to Figure 4

(A) Snapshots of 4sU-labeled RNA-seq signal tracks in siCtrl and siASF1 conditions focusing on annotations (blue bars) and regions downstream of the SL of the replicative histone genes H2BC11, H2AC11, H4C8 and the non-replicative histone genes H3-3B and H1-0. Stem loops and polyadenylation sites are respectively indicated by triangles and circles. Numbers above the tracks indicate ratios of the read counts mapping on the region downstream of SL over the read counts mapping the ORF for each replicative histone gene. (B) (Left) Scheme showing replicative histone pre-mRNA. The cleavage of the pre-mRNA occurs downstream of the Stem-Loop (SL) and upstream of the Histone Downstream Element (HDE). The detection of the indicated 49 nucleotides in RNA-seq fragments is diagnostic of pre-mRNA/unprocessed replicative histone transcripts. This fragment encompasses the cleavage site, from 20 nucleotides upstream of the SL (16 nt long) to 13 nucleotides downstream of the SL, reaching the HDE. (Right) We compared the fractions of unprocessed transcripts between siASF1 and siCtrl conditions using data from our total (~5.7-fold increase) and 4sU-labeled RNA-seqs (~1.34-fold increase) of asynchronous cells and from our total RNA-seq of synchronized cells (~2.8-, ~5- and ~21-fold increases at times 0, 2 and 5 hrs after release). The box plots show the ratio of the number of unprocessed transcripts to total transcripts (total number of reads mapping in each annotated replicative histone gene of Group 2). The results for the two replicates R1 and R2 are shown. The p-values for greater values in siASF1 compared to siCtrl are indicated. (C) Levels of oligo/poly(A)+ transcripts for replicative histone genes that are downregulated after ASF1 depletion (left panel) and for highly expressed genes (second decile of most highly expressed genes in synchronized cells) (right panel). We provide the spike-in normalized number of oligo/poly(A)+ reads. The two replicates (R1 and R2) for siCtrl and siASF1 conditions are shown. (D) Analysis of replicative histone pre-mRNAs/unprocessed transcripts by RT-qPCR amplifying sequence defined by "pre" primers (Figure 4B) on genes H1-4 and H3C14. We used total RNA isolated from HeLa cells harvested 48 hrs after siRNA transfection (siCtrl, siSLBP, siASF1a, siASF1b or siHIRA). We provided the fold changes in unprocessed transcript levels for siSLBP, siASF1a, siASF1b and siHIRA transfected cells relatively to siCtrl. See also supplementary Table.

SUPPLEMENTAL REFERENCES

- S1. Klimovskaia, I.M., Young, C., Strømme, C.B., Menard, P., Jasencakova, Z., Mejlvang, J., Ask, K., Ploug, M., Nielsen, M.L., Jensen, O.N., et al. (2014). Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication. Nat Commun 5, 3394. 10.1038/ncomms4394.
- S2. Silljé, H.H.W., and Nigg, E.A. (2001). Identification of human Asf1 chromatin assembly factors as substrates of Tousled-like kinases. Current Biology 11, 1068–1073. 10.1016/S0960-9822(01)00298-6.